Atrial fibrillation (AF) is the most common pathological cardiac arrhythmia affecting performance in horses. The prevalence of paroxysmal AF is unknown as the disease may go unnoticed by the trainer or rider due to the short duration of the AF episodes. Implantable Loop Recorders (ILRs) are small ECG devices placed subcutaneously, capable of automatically detecting and storing predetermined arrhythmic events. ILRs are used in human patients to detect AF and other arrhythmias and have shown superior diagnostic yield compared to surface ECGs for long term monitoring, although the function is highly dependent on the quality of the recorded signals.
The purpose of the present study was to evaluate the best anatomical localization for the ILR in horses in order to obtain a good quality ECG recording. By comparing three different anatomical positions in a horse developing AF, the ability of this new diagnostic technique to detect AF was described and compared to Holter surface ECG.
Three ILRs (Reveal Linq, Medtronic) were placed subcutaneously in local anesthesia at three different locations in a 13 year old Standardbred mare. One recorder was placed in the superficial pectoral region (Front), one was placed in the left sixth intercostal space at the level of the shoulder joint (Left) and finally the third recorder was placed ventrally at the level of the xiphoid process in a cranio-caudal direction (Ventral). The horse was tachypaced into AF by pacemaker stimulation and arrhythmic events were registered for a two months period by the ILRs. During the period, a Holter ECG was placed on the horse at selected time points.
All ILRs showed stable R wave amplitude and were able to detect the occurring AF episodes with the ILR at the Left position showing the highest R wave amplitudes compared to the other two positions (P < 0.001). P waves were only visible at the Left position. During AF, f waves were constantly visible (100%) prior to all R waves for the Left position compared to 80% and 13% for the Front and Ventral position, respectively. Movement artifacts for all three ILRs were rare and none of them lead to a false positive AF diagnose.
This study shows that ILRs can detect AF occurence in horses, but the anatomical location is essential for optimal ECG quality with the Left postion superior compared to the two other locations. ILRs may add diagnostic value in horses presented with poor performance or for detection of AF recurrence after cardioversion. Development of left ventricular hypertrophy is a late stage event in hypertrophic cardiomyopathy (HCM). Myofilament mutations generally enhance calcium sensitivity, maximal force production, and ATPase activity leading to energy deficiency and altered calcium handling as major common pathways promoting HCM irrespective of specific genotype.
EPIGALLOCATECHIN-3-GALLATE RECOUPLES MYOFILA-MENT CALCIUM SENSITIVITY TO TROPONIN I PHOS-
In the normal myocardium the contraction relaxation cycle is regulated by calcium and modulated by b-adrenergic stimulation leading to the phosphorylation of several key proteins which increase inotropy. In addition, phosphorylation of cardiac troponin I (cTnI) results in a faster dissociation of calcium from cardiac troponin C (cTnC) and decreases the sensitivity of the cardiac myofilament for calcium (lusitropy). Mutations in sacrcomeric proteins that cause HCM in humans and engineered rodents abolish the relationship between cTnI phosphorylation and increase calcium sensitivity even if the mutation is not in the troponin complex. This phenomenon has been termed uncoupling. Recently it has been shown that calcium desensitisers Epigallocatechin-3-gallate (EGCG) can restore the calcium sensitivity of the myofilament (at least in part) by "recoupling" the relationship between calcium sensitivity and cTnI phosphorylation.
The purpose of this study was to investigate if uncoupling was common in cats with HCM and whether it could be reversed using EGCG.
In vitro flow motility assays were performed with troponin extracted from 7 cats diagnosed with HCM including a ragdoll homozygous for the MYBPC R820W mutation and 5 wild type (WT) unaffected cats. All HCM cats had higher calcium sensitivity than the WT cats with an average increase of 1.8 times which is equivalent to the finding in human HCM patients. Uncoupling of calcium sensitivity from cTnI phosphorylation was observed in all 7 HCM cats examined whereas in all 5 WT cats coupling was normal. Furthermore, EGCG was tested in 1 WT cat and 3 HCM cats and was found to completely reversed the uncoupling in all HCM cats and reduce the calcium sensitivity to a level similar to WT cats. We performed protein transfer experiments which indicated that the uncoupling in HCM cats is linked to cTnT similar to what has previously been reported for HCM in humans.
EARLY EXPERIENCES WITH 3D MODELING AND PRINT-ING OF HEARTS WITH COMPLEX CARDIAC DISEASE.
Susanne M. Stieger-Vanegas. College of Veterinary Medicine, Oregon State University, Corvallis, OR, USA Three-dimensional (3D) models of computed tomography angiography (CTA) images provide the benefit of a haptic experience, allow manipulation and enhance the understanding of the cardiovascular anatomy and underlying pathologies.
The aim of this study was to create anatomically correct and precise 3D printed models of the heart of veterinary patients with complex cardiac disease to facilitate a better understanding of the complex cardiac abnormality.
Based on CTA images, regions of interest were segmented using the Mimics software (Materialise, Leuven, Belgium). The segmented areas were blood volume and cardiac surface or area of major abnormality. After generating a sterolithography (STL) file out of the patient's data set, the 3D printer created a 3D model. The patient's individual 3D printed models were evaluated for geometric accuracy by comparing measurements of the cardiac structures in the CTA images and 3D printed model. 3D models of hearts of veterinary patients with complex cardiac abnormalities can be created and printed. These 3D models were accurate and precise. The higher the quality and degree of contrast enhancement in the CTA images of the cardiac structures, the easier and faster the segmentation of the heart could be performed. The CTA images and measurements of the 3D models were similar.
3D modeling and printing is a novel technique, which allows to obtain accurate 3D models of hearts with complex cardiac disease. Once a 3D model is created it can be printed multiple times and made available for teaching. These 3D printed hearts or files could easily be shared between facilities. North Carolina State University, Cary, NC, USA Arsenical therapy has long been the basis for heartworm adulticidal therapies and is safe and effective when used as directed. Arsenical therapy, however, has limited availability periodically and is unavailable in many countries. Topical moxidectin/imidacloprid (M/I) is different than other macrocyclic lactone preventives, in that higher blood and tissue concentrations are reached and maintained for a longer period. M/I has also been shown to be safe and well tolerated at accelerated dosing protocols in dogs with demodectic mange.
USE OF MOXIDECTIN/IMIDACLOPRID AND DOXYCY-CLINE FOR NON-ARSENICAL
Eighteen dogs, positive for HW by antigen testing received M/I at the preventive dosage (2.5-7.4 mg/kg), yet given every 15 days for 90 days, then every 30 days thereafter. Concurrently, each dog received doxycycline for 15 days. Additional courses of doxycycline or minocycline could be given at the discretion of the clinician. Dogs were also tested for microfilaria on the day of diagnosis. Heartworm antigen tests were repeated on Day 90, 120, and 150, then every 60 days thereafter. When dogs became antigen-negative (by the conventional test), heat-treated serum was also tested. For dogs remaining HW antigen-positive after day 210, the owner was offered melarsomine therapy. If the owner elected to continue with the study protocol, then M/I was continued monthly at the preventive dosage. Dogs were not strictly exercise restricted.
At the time of this writing, 18 dogs have been entered into the prospective study, with 13 having completed the study. The median (interquartile range; IQR) age and weight of the 18 dogs was 4.9 (3.0-8.8) years and 24.8 (17.1-29.7) kilograms, respectively. The median (IQR) doxycycline dosage was 12.6 (12.0-16.1) mg/ kg/day. Three dogs received additional courses of doxycycline or minocycline at the attending clinician's discretion. Eight dogs developed a cough during M/I treatment. Treatment for cough included prednisone (n = 3), dexamethasone (n = 1), and dextromethorphan hydrobromide and guaifenesin (n = 1). Seventeen of the 18 dogs were tested for microfilaria upon study enrollment and 11 were microfilaremic. Eight of these dogs had additional microfilaria tests. This study was not designed to test the efficacy and speed of the microfilaricidal effect of M/I, yet the median (IQR) time to negative was 85 (59-111) days. For the 13 dogs that have finished, the median (IQR) time to the first negative on the (conventional) antigen test was 208 (162-282) days. Six dogs were also antigen-negative when the serum was heat-treated. Five dogs had a negative heat-treated test 33, 38, 41, 67 and 107 days after their conventional test was negative, and 2 dogs have not yet been re-tested. Five dogs remain antigen positive and the median (IQR) time that these dogs have been in the study is 340 (340-396) days. All five of these dogs are past study day 210 and when their owners were offered melarsomine therapy, they declined and elected to continue giving M/I once monthly.
The combination of M/I and doxycycline provides a potential alternative when/where aresenicals are unavailable. In some cases, the conversion to antigen-negative status using heat-treated serum will lag behind the conventional test. The clinical importance of this is not known, but at present, we do not advocate heat-treating serum to confirm negative status. Exercise restriction would likely have reduced the frequency of cough seen in this study. Though preliminary, these data suggest that, based on conventional antigen testing, the efficacy, safety, and convenience of this protocol is acceptable, when melarsomine cannot be employed. Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA, USA, 2 Tufts University, North Grafton, MA, USA Perceived QoL of a pet with heart disease is an important factor in owner decision-making. However, the owner's QoL may be an equally important factor in the care of a pet with heart disease.
VALIDATION OF A QUALITY OF LIFE SURVEY FOR OWNERS OF DOGS WITH
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Studies have assessed the QoL of caregivers for people with heart disease, but no studies have been reported on QoL for owners of pets with heart disease. Therefore, the purpose of this study was to develop and validate a questionnaire to assess self-reported QoL of owners of dogs with heart disease. A 7-item questionnaire was developed based on areas of a person's life that could be impacted by caring for a sick animal, with a possible range of 0-35, with higher scores indicating worse owner QoL. The survey was self-administered to owners of dogs with heart disease presented to the Cardiology Service. The owner questionnaire was evaluated for readability, face validity, criterion-related validity, and test-retest reliability. The International Small Animal Cardiac Health Council (ISACHC) classification of heart failure was used as an independent measure of the severity of dogs' disease and the Functional Evaluation of Cardiac Health (FETCH) questionnaire was used to assess the owners' perception of their dogs' QoL. The owner QoL questionnaire was completed by 217 owners of dogs with heart disease and repeated after one to three weeks by 11 owners. Underlying diseases included degenerative mitral valve disease (n = 164) and cardiomyopathy (n = 53). Dogs' ISACHC stages were 1a (n = 38), 1b (n = 108), 2 (n = 44), 3a (n = 25), and 3b (n = 2). Median FETCH QoL score was 7 (range, 0-70). Median owner QoL score was 6 (range, 0-31). The owner QoL score was correlated with the FETCH score (r = 0.76, P < 0.001) and the ISACHC stage (r = 0.53, P < 0.001). Test-retest reliability was high (r = 0.83, P < 0.001). These results suggest that the owner QoL questionnaire has good reliability and validity, and that further testing of this survey is warranted to optimize communication with owners regarding the care of dogs with heart disease. The interplay between cardiac and renal disease (cardio-renal syndrome (CRS)), is poorly understood in veterinary medicine. Type IV CRS describes cardiac dysfunction secondary to primary renal disease, however there is little data regarding the baseline cardiac function in dogs with chronic kidney disease (CKD). The study objective was to describe renal and cardiac function and biomarkers in a cohort of dogs with CKD. Dogs with IRIS stage 2 and 3 CKD and healthy dogs were studied. Dogs were excluded if they were < 10 kg, hypothyroid, had a heart murmur, evidence of primary cardiac disease, or active urine sediment, or were receiving glucocorticoid or diuretic therapy. Dogs with CKD were examined 6 months apart. Standard echocardiography and blood and urine tests as well as symmetric dimethylarginine (SDMA), glomerular filtration rate (GFR) by iohexol clearance, plasma cardiac troponin I and N-terminal-pro-B-type natriuretic peptide (NT-proBNP), and urinary clusterin, cystatin B and neutrophil gelatinase-associated lipocalin (NGAL) were measured. Groupwise comparisons were made using one-way ANOVAs or Kruskall-Wallis tests, as appropriate.
INFLUENCE OF CHRONIC
Twenty-three dogs were recruited (12 healthy controls, 5 IRIS stage 2 and 6 IRIS stage 3). Significant differences among groups were detected for body condition score (P = 0.044), PCV (P = 0.005), sodium (P = 0.005), BUN (P = 0.002), creatinine (P < 0.001), SDMA (P < 0.001), GFR (P < 0.001), NT-proBNP (P = 0.005), USG (P = 0.001), UPC (P = 0.001), cystatin B (P = 0.006), NGAL (P = 0.010) and E wave velocity (P = 0.047). No variables changed significantly between visits.
In conclusion, E wave velocity and various biomarkers increased with increasing CKD severity, suggesting that cardiac function is affected by declining renal function. Obtaining an accurate measurement of an angiographic structure is critical for successful intervention. The accuracy of a measurement depends on both precise measurement of the lesion and an accurate reference calibration to compensate for image magnification. The aim of this study was to evaluate angiographic measurements using two commonly employed reference calibration methods, an esophageal marker catheter (C) versus a table ruler (R).
ACCURACY OF ANGIOGRAPHIC MEASUREMENTS DUR-
Twenty-five dogs undergoing transcatheter intervention were prospectively enrolled. Interventions included balloon pulmonary valvuloplasty (PS, n = 14), balloon aortic valvuloplasty (n = 1), ductal occlusion (PDA, n = 8), or cor triatriatum membranostomy (CTD, n = 3) from May 2016 to February 2017. All angiograms were reviewed and relevant measurements performed in triplicate and averaged when calibrated to either C or R. Comparisons between methods were made by paired t-test and the method of Bland and Altman.
Measurements were larger when calibrated to C versus R (P < 0.0001). The mean bias was 0.8 mm having 95% limits of agreement from 0.1 mm to 1.7 mm, with greater bias for larger measurements. These differences persisted when PDA and PS cases were analyzed individually (P = 0.0003 and P < 0.0001, respectively), but were not significant for CTD cases alone (P = 0.051).
Calibration of an angiographic image using a ruler placed on the fluoroscopy table during transcatheter procedures underestimates the actual size of a structure, when compared to a calibrated esophageal marker catheter placed at the same level as the heart. This effect is greatest when measuring larger structures such as the pulmonary valve annulus. Randomized controlled clinical trials (RCT) offer the best approach for questions with clinical equipoise. However, funding sources for RCT in veterinary cardiology are sparse. Therefore, we utilized a short survey to assess the possibility of developing a cost-effective infrastructure for multicenter RCT specific to veterinary cardiology to answer simple, relevant, clinical questions with pragmatic end-points.
We distributed the survey to 605 members of a cardiology list serve of diplomates, residents, certificate holders and clinicians interested in cardiology. The survey was completed by 155 respondents (32 provided partial responses) composed of 81 cardiology diplomates, 12 certificate holders, 7 residents, 6 other, and 49 undeclared. A majority of respondents (n = 133, 86%) declared an interest in contributing cases, 11 (7%) supported the concept but lacked time to be involved, and 2 (1%) felt the concept would not succeed. Of the 3 conditions proposed as initial studies, 75% of respondents considered the highest priority to be beta-blocker treatment of feline subclinical hypertrophic obstructive cardiomyopathy, followed by canine subaortic stenosis (15% of respondents) and canine pulmonary valve stenosis (10% of respondents). Estimated case numbers by respondents suggested that robust sample sizes could be anticipated for these studies, resulting in high power for addressing these questions.
Our results suggest widespread interest in developing an infrastructure for multicenter RCT in veterinary cardiology, as has been done successfully by other specialties (e.g. veterinary oncology). Further analyses of the survey will be presented and the INSPECT framework will be proposed for discussion. Abnormalities in cerebrospinal fluid (CSF) flow are described in dogs and humans, particularly in association with craniocervical junction (CCJ) anomalies, arachnoid scarring and syringomyelia. In cats, although subarachnoid and spinal cord pressure changes have been described caudal to focal arachnoid scarring, 1 and secondary syringomyelia has been suspected to result from intracranial/CCJ anomalies, 2 CSF flow has not yet been characterized in this species. We aimed to use phase-contrast MRI (PCMRI) to measure normal CSF flow parameters in cats and develop novel software to automate flow analyses.
Ten healthy, neurologically normal, domestic shorthaired cats were imaged with a 3T MRI unit. T2-weighted sagittal sequences were used to rule out structural brain, CCJ and cervical spinal cord abnormalities. With the CCJ in extended (i.e. straightened) and flexed positions, CSF flow velocities, stroke volume, and flow rates were measured at the atlantooccipital, C1-C2 and C2-C3 junctions using PCMRI.
Flow could be assessed in all cats at all levels, although atlantooccipital junction flow was best assessed in flexion. Flow velocities were lower than those reported in dogs and humans. In preliminary analyses, peak systolic velocities were higher at the atlantooccipital and C12 junctions when positioned in extension; peak diastolic velocities were also higher in extension at the atlantooccipital junction. Surface area, stroke volume, and flow rates did not vary significantly with position.
In conclusion, PCMRI can be effectively used to measure CSF flow in cats. Feline CSF flow is slower than that of dogs and humans, and may be influenced by head and neck positioning.
References: The Adamo Spinal Disc TM is an articulating surgical implant used to treat Disc-Associated-Wobbler Syndrome in dogs. Material for the articulating connection between the two vertebrae must resist shear, compressive forces, and be resistant to wear and fatigue failure.
An articulating ball was created using three Polyether-etherketone (PEEK) composites [Virgin PEEK (V-PEEK), 30% GlassFiber-PEEK (GF-PEEK), 30% Carbon-Fiber-Reinforced PEEK (CFR-PEEK) ] to compare biomechanical properties. Three replicates were tested by aligning the two mating faces of the titanium discs with a PEEK ball and loading the construct in shear to failure at 0.01 mm/sec in a mechanical testing system. One construct with each PEEK ball was loaded in compression to 0.2 mm displacement at 0.01 mm/sec, i.e., until the space closed between the metal faces.
In shear, GF-PEEK was 40% stiffer and CFR-PEEK was 60% stiffer than V-PEEK. GF-PEEK was 20% stronger and CFR-PEEK was 30% stronger than V-PEEK. GF-PEEK had 370% less post-yield energy and CFR-PEEK had 170% less post-yield energy than V-PEEK. In compression, CFR-PEEK was 3 times as stiff and twice as strong as V-PEEK and GF-PEEK in the linear elastic region.
CFR-PEEK was stronger and stiffer than V-PEEK and GF-PEEK, making it more resistant to acute failure. Based on these findings, CFR-PEEK appears to be the best suited for articulating implants. However, V-PEEK was highly ductile and tough, properties that may contribute to longer fatigue life. Because fibers in CFR-PEEK also contribute to increasing fatigue life, further studies investigating fatigue life associated with chronic repetitive motion are warranted. The purpose of this case-control study is to identify specific triggers significantly associated with development of granulomatous meningoencephalitis (GME), necrotizing leukoencephalitis (NLE), and necrotizing meningoencephalitis (NME) in this population of dogs. A retrospective review of the hospital records database identified 31 dogs with adequate historical information diagnosed with GME, NME, or NLE on histopathologic examination at necropsy from 2003-2015. Three matched (age-breed-year of presentation) control dogs were randomly selected from the hospital population for each case dog. One case had only one control match available. GME, NME and NLE are inflammatory diseases of the central nervous system in dogs that are suspected to be immune-mediated in at-risk individuals; however, a trigger has yet to be identified. Triggers such as geographic location, temporal association with vaccination, sex, seasonal distribution, obesity, and population density have been investigated for other animal and human immune-mediated diseases with variable results. No association between body condition score (P = 0.72), weight (P = 0.28), temporal relationship to vaccination (P = 0.40), or population density (P = 0.45) was found in this study. Male dogs were more likely to develop disease compared with female dogs (P = 0.02). In summary, no significant association between select triggers and the development of GME, NLE, and NME was identified. The association with sex may suggest a hormonal influence on development of disease. Pursuit of other triggers, such as exposure to infectious agents, toxins, and animal crowding, could be investigated in future studies. The purpose of this study was to determine if once daily administration of extended-release levetiracetam for 10 days in cats can achieve serum concentrations above the minimum human therapeutic interval (5 mcg/mL) and to evaluate side effects during the treatment course. Eight healthy staff-or student-owned cats weighing more than 5 kg body weight were enrolled. Extended-release levetiracetam (500 mg once daily) was administered for 10 days with food. On day 11, median serum levetiracetam concentrations at 0, 4, 6, and 8 hours post pill were 7.0, 78.6, 92.7, and 72.2 mcg/ mL, respectively. Mean estimated Tmax was 6.3 hours (range: 4-8 + hours). Samples for some time points were not collected from 2 cats owing to lack of cooperation. Six of 8 cats had serum levetiracetam concentrations above 5 mcg/ml time 0. The neurologic examination was normal for all cats on the day of sampling. No significant changes were noted on serum biochemical analysis on day 11 compared with the day of enrollment. Side effects were limited to mild ataxia on day 1 in one cat. The results from this study suggest that once daily administration of 500 mg extended-release levetiracetam in cats weighing more than 5 kg is well tolerated and able to provide serum concentrations above the minimum human therapeutic interval at time 0 in the majority of cats. Peak and trough samples and seizure monitoring should be considered on an individual basis for epileptic cats.
EVALUATION OF RISK FACTORS
SERUM LEVETIRACETAM CONCENTRATIONS AFTER
EXPERIMENTAL THERAPIES FOR CANINE KRABBE DIS-EASE. Allison Bradbury. University of Pennsylvania, Philadelphia, PA, USA Globoid cell leukodystrophy (GLD), or Krabbe disease, results from a deficiency in the hydrolytic enzyme galactosylceramidase (GALC), which is responsible for degrading the central and peripheral nervous system (CNS, PNS) myelin lipids galactosylceramide and galactosylsphingosine (psychosine). Symptoms in infants include irritability and stiffness with disease progressing rapidly to a vegetative state and death typically resulting by 2 years of age. GLD is naturally occurring in dogs and signs include ataxia, tremors, pelvic limb paralysis, loss of hearing, and blindness, with disease progression warranting euthanasia at 15.9 AE 4.6 weeks. Motor and sensory conduction velocities in peripheral nerves of GLD dogs are significantly reduced compared to normal and brain stem auditory evoked response testing exhibits a significant increase in central conduction time, both consistent with demyelination. Magnetic resonance imaging of the brain shows T2-weighted hyperintensity of the white matter, widened sulci, and enlarged ventricles and magnetic resonance spectroscopy identified decreases in N-acetylaspartate and increases in choline. Diffusion tensor imaging established decreased fractional anisotropy and increased radial diffusivity in multiple white matter tracts including the corpus callosum and posterior internal capsule. Histologically, GLD dog brains show severe loss of myelin, a decrease in oligodendrocytes, astrogliosis, and microgliosis.
Gene therapy has been evaluated in GLD affected dogs using AAVrh10 encoding canine GALC (AAVrh10-cGALC). Two GLD dogs received a low dose of AAVrh10-cGALC, 1.2E12 total vector genomes divided evenly between combination intravenous (IV) and intracerebroventricular (ICV) injection routes and survived to 17.9 and 22.1 weeks of age. Two additional GLD dogs were treated with an increased dose, 1.9E13 total vector genomes, and survival was further increased to 30.3 and 43.1 weeks of age. Both low and high doses prevented the onset of tremors and delayed the onset of other neurological dysfunction. High dose AAVrh10-cGALC, but not low dose, resulted in normalization of peripheral nerve conduction velocity. After high dose treatment, GALC activity reached normal levels in the cerebellum and sciatic nerve and psychosine accumulation was reduced. High dose AAV resulted in CSF psychosine concentrations lower than untreated and low dose AAV-treated GLD dogs, despite being older. Histologically, the therapy largely attenuated the loss of myelin, accumulation of storage material, and onset of neuroinflammation. AAV gene therapy targeted to the CNS and PNS delayed the onset neurological dysfunction, increased survival, and corrected pathology in the canine model of Krabbe disease.
GENE THERAPY IN ANIMAL MODELS OF THE GAN-GLIOSIDOSES: FROM PRESENTATION TO HUMAN CLINI-CAL TRIALS.
Heather L. Gray-Edwards. Auburn University, Auburn, AL, USA GM1 and GM2 gangliosidosis (Tay-Sachs, Sandhoff disease, GM2 activator protein deficiency) are monogenetic diseases that result from deficiencies of b-galactosidase (b-gal), hexosaminidase (Hex), or GM2 activator protein, which are enzymes of the ganglioside degradation pathway. These are global diseases resulting in ganglioside buildup in all tissues, but have primary neurodegenerative presentation due to the inherent concentration of gangliosides within neurons. These diseases are clinically indistinguishable in humans and symptoms present in children with lack or loss of developmental milestones (sitting, crawling, etc.) and progress to inability to swallow, seizures and eventual semi-vegetative state. As with most human diseases, these diseases are also naturally occurring in animals (cats and sheep), and are maintained for study and testing of novel therapeutics.
Cats with GM2 gangliosidosis have a deficiency in the b-subunit of the isoenzyme hexosaminidase and have the genetic equivalent of Sandhoff disease in humans. Affected cats exhibit a profound cerebellar phenotype with resting and intention tremors that progress to severe ataxia an inability to stand at 4.5 + /-0.5 months. GM2 cats also exhibit a mucopolysaccharidosis like phenotype with skeletal abnormalities and glycosaminoglycan storage. Cats with GM2 develop prolonged latencies in waves II, III and V on brainstem auditory evoked responses (BAER). 7T T2 weighed (T2w) MRI shows an intensity inversion, where white matter becomes hyperintense to surrounding gray matter correlating with cell body storage of GM2 and demyelination. MRS reveals severe cerebellar disease with a large increase in the toxic metabolite Nacetylhexosamine and elevations in demyelination markers glycerophosphocholine and phosphocholine (GPC+PCh) and the glial cell marker myoinositiol (INS). Cerebrospinal fluid (CSF) levels of aspartate aminotransferase (AST), lactate dehydrogenase (LDH) increase with disease severity.
GM2 gangliosidosis sheep have a deficiency in a-subunit of hexosaminidase and have the genetic equivalent of Tay-Sachs disease in people. GM2 sheep present with proprioceptive deficits, also develop generalized proprioceptive ataxia and eventually lose the ability to ambulate at 9.4 AE 0.8 months. Approximately 10% of GM2 sheep exhibit loss of consciousness episodes that are suspected epileptic events. Sheep exhibit continuous semi-rhythmical slowing of neural oscillations with a predomination of delta waves on electroencephalography (EEG), with superimposition of sharp spike discharges. On 7T T2 weighed (T2w) MRI, the brain develops areas of isointensity due to ganglioside storage and demyelination, which are most evident in the cingulate gyrus, parietal cortex and temporal lobes. MRS reveals the greatest disease severity in the thalamus with a reduction in neuronal markers N-actetylaspartate (NAA), glutamine + glutamate (GLX) and increases in GPC+PCh, taurine and INS. Elevations of AST, LDH, and GM2 ganglioside as well as other sphingolipids were noted in the CSF of TSD sheep.
Adeno-associated (AAV) gene therapy is ideal for treatment of monogenetic neurologic disorders. We performed intracranial injection of AAV gene therapy that has resulted in widespread distribution of the encoded therapeutic protein(s) and increased survival in in all three diseases. AAV treated GM1 cats are now living into the 7th year of life with mild neurologic disease and seizures that a largely controlled with anti-epileptics. AAV treated GM2 cats survival has increased to almost 3 years of age (a >four-fold increase in lifespan), with marked improvement in neurologic disease with the largest therapeutic limitation being peripheral dysfunction. AAV treated GM2 sheep are now living to almost 2 years of age with the largest therapeutic weakness being reduced distribution to the spinal cord. Success of these studies in animals has led to submission of pre-Investigational New Drug (IND) applications with the FDA and clinical trials for both GM1 and GM2 gangliosidosis are anticipated to start within the next year.
AAV GENE THERAPY STUDIES IN THE FELINE MODEL
OF NIEMANN-PICK TYPE C. Brittney L. Gurda. University of Pennsylvania, Collegeville, PA, USA Niemann-Pick type C1 (NPC1) disease is characterized by progressive cerebellar ataxia, dementia, and death in adolescence. It is caused by mutations that result in deficient function of lysosomal, membrane-bound NPC1, resulting in the intralysosomal accumulation of cholesterol and sphingolipids. There are no FDA-approved therapies for NPC1 disease, however, we have previously shown that administration of 2-hydroxypropyl-beta-cyclodextrin (HPßCD) via the cerebromedullary cistern (CBMC) in presymptomatic cats with NPC1 disease prevented the onset of cerebellar tremor and resulted in Purkinje cell (PC) survival and near normal concentrations of cerebral cortex and cerebellar cholesterol and sphingolipids. Remarkably, these cats remained alive for greater than three years of age, in contrast to untreated NPC1 cats that died before six months of age. This therapy has advanced to clinical trials where patients receive biweekly HPßCD.
In an attempt to both reduce the number of HPßCD injections and to treat uncorrected brain regions, we studied the feasibility of viral gene therapy, providing a one-time injection, in NPC1 cats. Preliminary studies utilized administration of an adeno-associated virus (serotype 9; AAV9) carrying the feline NPC1 transgene (AAV9.fNPC1) via the CBMC of pre-symptomatic NPC1 cats. These treated cats showed reduced ataxia compared to untreated cats. Histologic evaluation of the brains revealed that NPC1 expression had been restored to some PCs and that this was associated with increased PC survival. This initial success prompted us to further explore the potential of various promoters to express functional NPC1 protein in the brain. In this study we evaluated the ability of four different promoters, three ubiquitous (CB7, GUSB, and USP) and one neuron-specific (CamKII), to drive GFP expression in the central nervous system of normal cats.
Our preliminary therapeutic studies used the GUSB promoter (pGUSB) to mediate fNPC1 expression. Expression of both fNPC1 and a GFP reporter under pGUSB were low in PCs, and in cerebrocortical neurons and astrocytes. Overall, the CB7 promoter drove the highest level of expression in similar regions; however, this large promoter (~970 bp) limits transgene size (where NPC is~4.3Kbp) and led us to examine a smaller exogenous promoter based on CB7 (termed USP; UNC via Dr. Steven Gray). This promoter was similar in expression levels to the pGUSB, leading to low-level expression at our limit of detection using DAB-based immunohistochemistry. Interestingly, a 6-month therapeutic study using the USP promoter had a similar outcome as pGUSB where treated cats had reduced clinical signs at the end of study. Expression driven by the neuron-specific promoter CamKII produced levels similar to the CB7 promoter, although PCs of the cerebellum had low to undetectable expression levels. These data and preliminary therapeutic data in AAV-treated NPC1 cats will be further explained in this presentation.
GENERATING NOVEL LARGE ANIMAL MODELS OF NER-VOUS SYSTEM DISEASE FOR THERAPEUTIC STUDY
USING THE CRISPR/CAS9 SYSTEM. Brittney L. Gurda. University of Pennsylvania, Collegeville, PA, USA Large animal models of disease continue to play a strong role in the advancement of novel therapies into the clinical setting. While numerous naturally occurring models of disease have been previously identified, the rates at which new mutations are found and characterized generate a significant bottleneck in the field. With advancements in cloning strategies we now harness a more direct way to target mutations in the genome and thus generate large animal models for study. The most recent technological advances in cloning are based on an immune defense mechanism identified in bacteria and archaea. This novel system uses clustered regularly interspaced short palindromic repeats (CRISPRs) and their associated proteins (Cas) to guide a small section of foreign DNA into the host genome that leads to immunity against the invader1. Specifically, the CRISPR/Cas9 system has recently been repurposed to initiate genome engineering in cells, tissues, and animals as well as novel treatment strategies for genetic and infectious diseases.
In this study we sought to generate a novel feline model of neurological disease using the CRISPR/Cas9 system. Niemann-Pick disease, type C (NPC), is a recessively inherited neurodegenerative lysosomal storage disease characterized by the accumulation of low-density lipoprotein-derived unesterified cholesterol in the late endocytic organelles. Both NPC1 and NPC2 proteins participate in the egress of cholesterol from cells and disruptions in either of these genes have been associated with NPC disease. About 90-95% of mutations occur in the NPC1 gene while the remaining 5% are attributed to disruptions in NPC2. Since a NPC type C1 model already exists and has been well characterized in felines, we sought to create an NPC2 model that will compliment our NPC1 feline model studies. Using a naturally occurring defect previously identified in a domestic cat2 and the CRISPR/Cas9 system we have successfully generated a single-nucleic acid mutation in the NPC2 gene of feline zygotes. Implantation of NPC2-defective zygotes into surrogate female cats is currently underway and methodical data leading up to and beyond the implantation stage will be discussed in this presentation. Hansen first described type I intervertebral disc disease (IVDD) in the dog using five breeds, which he classified as chondrodysplastic: French bulldog, Dachshund, Pekingese, Dachsbrache and the Spaniel. Dogs from these breeds have abnormal long bone growth plates, abnormal vertebral growth, and abnormal intervertebral disc material, referred to as endochondrosis intervertebralis. Later, Braund performed systematic histopathological analysis of the Beagle breed and classified it as chondrodystrophoid-like with the same predisposition to type I disc herniation. While these breeds are not all severely disproportionately short legged, they all share the common features of abnormal endochondral ossification of long bones leading to shorter legs. The Nova Scotia Duck Tolling Retriever is a medium sized dog and the smallest of the retriever breeds. They have a form of skeletal dysplasia that in its severest form has been likened to chondrodysplasia. We performed a genome wide association study (GWAS) for this severe phenotype using the Illumina 174K single nucleotide polymorphism (SNP) array and obtained a significant association (p raw = 6.803 9 10 À8 , p Bonferroni = 0.007232) on chromosome 12. Underlying this association was a large region of homozygosity. When sharing of this region was investigated with other breeds, portions of it were shared with Beagles, Dachshunds, American Cocker Spaniels, Pekingese and French Bulldogs, the same breeds predisposed to Type I IVDD. In order to investigate the association with diseased animals, samples were collected from 36 dogs with presence of mineralized intervertebral discs confirmed by vertebral column radiographs and/or magnetic resonance imaging followed by surgery. These dogs were selected from many different breeds and mixed breed dogs. A statistically significant (p raw = 3.191 9 10 À15 , p Bonferroni = 9.438 9 10
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) genome wide association to the same region on chromosome 12 was obtained, which narrowed the critical interval to~1 MB. The most associated SNP from the GWAS was 32.67 (95% CI = (30.12, 35.44)) times more likely to be present in dogs with IVDD than in healthy dogs. Genes within the area were evaluated for expression in neonatal disc from predisposed animals and healthy animals. Whole genome sequence data was mined to identify the causative mutation, which has an odds ratio of 51.23 (95% CI = (46.69, 56.20)) for Hansen's Type I disc disease across all dog breeds. In addition, this mutation segregates in the majority of breeds where it is found allowing elimination of this disease from dogs. The hearing ability has a promising effect on human-animal bonding. The purpose of this study was to evaluate any otopathologic changes in temporal bone specimens of dogs with hereditary deafness. Specimens were obtained from the temporal bone collection of Otopathology Laboratory at the University of Minnesota. Temporal bone collection consisted of dogs clinically confirmed with hereditary deafness or hearing ability.
COCHLEAR CHANGES IN DOGS
Morphometric analysis included the measurement of the stria vascularis and spiral ligament areas and the count of spiral ganglion cells. In addition, the presence of the organ of Corti and cochlear hair cells are noted. The location of Reissner's membrane was also assessed.
The results of this report indicated a generalized degeneration in the cochlea including deformed Organ of Corti and Tectorial membrane, collapsed Reissner's membrane and loss of spiral ganglion cells (P < 0.05) in addition to lateral wall changes including decreased area (P < 0.05)of stria vascularis, spiral ligament and spiral prominence in deaf dogs. Hereditary deafness is untreatable with current known therapeutic methods; therefore, these animals may not be considered for breeding and future therapeutic approaches should be designed to target all the elements of the cochlea. The aim of this study was to evaluate the feasibility and effectiveness of curative high dose hypofractionated (HDH) frameless volumetric modulated arc radiotherapy (VMAT) in trigeminal peripheral nerve sheath tumours (PNST).
VOLUMETRIC MODULATED ARC RADIOTHERAPY
A prospective clinical trial was conducted from February 2010 to December 2013 on client-owned dogs with presumptive imaging-based diagnosis of trigeminal PNST. Seven dogs were enrolled and treated with 37 Gy in 5 fx using a 6 MV linear accelerator equipped with an external micro-multileaf beam collimator. The plans were computed using a Monte Carlo algorithm. Overall survival was estimated using a Kaplan-Meier curve analysis.
MRI follow-up examinations revealed complete response in one dog, partial response in four dogs, and stable disease in two dogs. Median overall survival was 952 days with a 95% confidence interval (CI) of [543Ä1361] days.
VMAT appears to be feasible and effective and offers the best median survival time in dogs suffering from trigeminal PNST compared with other radiotherapy treatment modalities, such as LINAC cone based radiotherapy or surgery.
Further informations available on website www.lacittadina.org. Treatment of canine peripheral nerve sheath tumors (PNSTs) is challenging, and prognosis after surgical resection is considered poor. The aim of this study was to evaluate the feasibility and the effectiveness of stereotactic radiotherapy of these tumors.
FRAMELESS STEREOTACTIC VOLUMETRIC MODU-LATED ARC RADIOTHERAPY OF BRACHIAL PLEXUS
Dogs with clinical signs and MRI findings consistent with PNSTs of the brachial plexus, branches and nerve roots were treated with LINAC-based volumetric modulated arc radiotherapy (VMAT) with a dose of 35 Gy/5 fractions. Clinical and MRI follow-up examinations were planned and radiotoxicity and survival times investigated.
Ten dogs were enrolled. Tumors involved the plexus and proximal nerves in three dogs, the plexus, proximal nerves and nerve roots in five dogs and the nerve roots and proximal nerves in two dogs. Partial or complete reductions of neurological deficits were observed in all treated dogs. Partial responses were observed in 10/10 patients. Local recurrence was observed in 9/10 of treated dogs. Mean overall survival of 371 days and mean progressionfree survival of 240 days are comparable to surgical literature data regarding the plexus and proximal nerve localization but are superior in comparison to nerve root localization.
VMAT can be a safe and viable alternative to surgery in cases of canine brachial plexus PNSTs involving the proximal nerves and nerve roots.
To our knowledge, this is the first prospective observational clinical study regarding VMAT stereotactic RT for canine brachial plexus PNSTs and suggests that VMAT may achieve at least similar clinical outcome than surgery in a safer way.
Further informations available on website www.lacittadina.org. Acute, severe thoracolumbar spinal cord injury (TLSCI) results in variable recovery. Plasticity of local spinal circuitry has been demonstrated in rodent SCI models. We hypothesized that reorganization of reflex circuitry including altered motor neuron excitability contributes to recovery of pelvic limb stepping in dogs with severe TLSCI. Our aim was to quantify motor neuron pool excitability electrophysiologically in normal dogs and dogs with chronic deficits due to acute TLSCI and correlate findings to gait.
Nineteen dogs without pain perception at least 3 months following acute TLSCI were prospectively enrolled and compared to 5 normal dogs. H reflex was evaluated. Gait was categorized as ambulatory (yes/no) and quantified using an ordinal scale (OFS) and treadmill-based stepping and coordination scores (SS, RI). H latency, H:M ratio, H threshold intensity were compared between cases and controls using student's t-test and investigated for associations with gait using linear regression.
H threshold in cases (mean:2.87 mA+/À2.4) was significantly lower than controls (mean:6.9 mA+/À4.3, P = 0.016). H threshold was not associated with walking, OFS (P >/= 0.05) but was inversely associated with SS (P = 0.031), RI (P = 0.029). No differences in H latency and H:M ratio (P > 0.05) were identified between cases and controls and these were not associated with gait.
These findings establish reference values for H wave variables in dogs with permanent deficits after TLSCI. H threshold might be a useful measure of motor neuron pool excitability in this population. These findings suggest dogs with greater excitability manifest greater stepping after injury. The variability and complexity of lesions amongst chronically paralyzed dogs after acute, functionally complete thoracolumbar spinal cord injury (TLSCI) is poorly understood. We hypothesized that Diffusion Tensor Imaging (DTI) would capture lesion heterogeneity in dogs with permanent deficits following TLSCI better than standard magnetic resonance imaging (MRI) sequences.
DIFFUSION TENSOR IMAGING ANALYSIS OF SEVERE
Twenty-one dogs without pain perception at least 3 months following acute TLSCI were enrolled and compared to 6 control dogs. All dogs underwent standard thoracolumbar MRI with DTI. Fractional anisotropy (FA) and mean diffusivity (MD) were calculated on regions of interest (ROI) at the lesion epicenter and cranial and caudal to the visible extent of the lesion in normal-appearing areas on conventional MRI. FA and MD were calculated on corresponding ROI in controls. Tractography was performed to detect translesional fibers. FA and MD values were compared between cases and controls using Wilcoxon rank sum test.
FA These findings suggest quantitative DTI can detect the cranialcaudal extent of severe TLSCI better than standard MRI and tractography may identify physical transection. DTI could allow for establishment of a continuum of severity amongst chronically paralyzed dogs following severe TLSCI. Standard treatment of non-ambulatory dogs with acute intervertebral disc herniations (IVDH) is surgical decompression. Following surgery, recommendations for management range from a period of strict rest to early intensive rehabilitation and the most appropriate management is unclear. This randomized, blinded trial compared the effect of a conservative versus an intensive rehabilitation protocol on gait score and coordination.
THE EFFECT OF POST-OPERATIVE REHABILITATION ON
Thirty non-ambulatory dogs treated surgically for acute IVDH were recruited and entered the trial on day 2 after surgery. Dogs had to be paraparetic or paraplegic with pain perception. They were randomized 1:1 to a conservative protocol of passive range of motion and sling walking or an intensive staged rehabilitation protocol. Dogs were treated for 2 weeks and had daily neurological examinations and videotaped gait acquisition on days 1, 14 and 42. The primary outcome was gait and coordination score at 14 days.
Thirty dogs completed the trial. All recovered independent ambulation and intensive rehabilitation was well tolerated with no adverse events recorded. Mean gait score at 2 weeks was 7.8/ 12 + /-1.2 and coordination score was 53.4% +/-35. There was no difference in gait score or coordination at 14 days between groups (P > 0.05). Gait and coordination scores improved to 9.4/ 12 + /-1.2 and 70.4% +/-24.8 by 42 days, again with no significant differences between groups (P > 0.05).
We conclude that early intensive rehabilitation is well tolerated by postoperative dogs, but does not influence the final gait grade or coordination in dogs with incomplete spinal cord injuries. Grenada. Clinical data and population characteristics including; the signalment, clinical signs, island location, tumour size, number of treatments, speed of regression of tumours, and concurrent diseases in CTVT were collected. This is a portion of data collected in conjunction with a worldwide genetic study "Mitochondrial genetic diversity, selection and recombination in a canine transmissible cancer" (Strakova and Leathlobhair et al 2016); where 449 complete mitochondrial genomes (mtDNAs) that track two millennia of dog global migration were sequenced. Five different tumour clades from 39 countries over 6 continents were identified. Mutations have occurred and captured in the canine infectious tumours highlighting the role of mtDNA in cancer evolution.
ONCOLOGY
Fifty Grenadian CTVT dogs were selected through the Pothounds Against Pregnancy program, with IACUC and European ethical standards approval. Clinical and patient data were collected upon presentation to the St. George's University Junior Surgery and Anesthesia Laboratory and tissue samples for genetic analysis were obtained during ovariohysterectomy or castration. Idexx 4DX SNAP was performed concurrently. Illumina Platform sequencing in the Wellcome Sanger Trust Cancer Genome Laboratory was utilized to perform low coverage whole genome sequencing, genome analysis and genome variant calling. With the aim of estimating the frequency and timing of mtDNA horizontal transfer, CTVT was confirmed with quantitative PCR to detect LINE-MYC genomic rearrangements.
All of the treated dogs currently living have undergone complete clinical cure. Three dogs were lost to follow up, with one showing possible side effects of vincristine treatment. The mutations found include 1005 single point mutations and 27 indels revealed 5 distinct CTVT mtDNA clades with independent origins. The population descriptors of the 50 Grenadian TVT dogs and the worldwide mapping of these mutations will be presented.
There is variability in the population characteristics in our Grenada CTVT dogs. The number of treatments varied as well as the Idexx 4DX SNAP test results. The genetic data is still under analysis and we hope to identify a correlation with the CTVT genomic changes and the different treatment responses. The Grenada CTVT mapped to both Clade 2 and Clade 3, revealing dynamic recent history of CTVT lineage. Published reports describe the effect of human cancers on circulating monocyte populations and macrophage polarization within the tumor microenvironment. We have previously reported defects in monocyte chemotaxis from dogs with osteosarcoma. However, there is much less information regarding the effects of osteosarcoma on canine macrophage polarization. M1 type macrophages are typically associated with inflammation and heightened antigen processing and presentation. M2 type macrophages exhibit more heterogeneity, but in general are associated with wound healing and immunosuppressive cytokine production. We hypothesized that canine osteosarcoma induces a macrophage phenotype more closely related to the M2 phenotype, which may ultimately contribute to tumor progression and the development of metastases. The primary purpose of this study was to compare cytokine profiles of canine macrophages cultured with or without osteosarcoma. Macrophages were cultured from canine peripheral blood monocytes obtained from healthy control dogs, and either maintained as macrophages cultured alone, or cocultured with osteosarcoma cells (Abrams canine osteosarcoma cell line). Culture supernatants were analyzed using a canine-specific multiplex assay for IFN-c, TNF-a, MCP-1, IL-10, and an ELISA for TGF-b. Macrophages cocultured with osteosarcoma secreted increased levels of both inflammatory (TNF-a) and anti-inflammatory (IL-10, TGF-b) cytokines compared to macrophages cultured alone. To further evaluate the phenotype of these cultured macrophages, we analyzed various macrophage markers (CD11b, MHCII, CD206, iNOS, and arginase) using flow cytometry. Our findings indicated that macrophages cocultured with osteosarcoma exhibited increased MHCII expression and suggested polarization to an M2-like phenotype. Symmetric dimethylarginine (SDMA) is a product of arginine metabolism that is cleared by the kidney. It is considered a more sensitive and specific biomarker than serum creatinine for the diagnosis and staging of chronic kidney disease in dogs. It is possible that serum SDMA levels may be increased in animals with malignancies because of increased protein metabolism. We observed that some dogs with untreated lymphoma appeared to have disproportionately increased serum SDMA levels compared to other biomarkers of kidney function, and that SDMA levels normalized when the dogs achieved remission. A previous study in humans reported that asymmetric dimethylarginine, but not SDMA levels, may be increased with hematologic malignancies, including nonHodgkin's lymphoma (Szuba et al. Leuk Lymphoma 2008;49:2316-2020). A preliminary study in dogs reported that SDMA levels may be increased in tumor-bearing dogs with normal creatinine levels, which was attributed to kidney disease or neoplastic infiltration (Yerramilli et al. J Vet Intern Med 2017;31:251), but changes in SDMA levels after treatment were not reported. Therefore, the purpose of this study was to retrospectively and prospectively investigate the effect of lymphoma on SDMA levels in dogs. Cases were retrospectively identified in autumn 2016. Prospective case enrollment began December 1, 2016.
IN VITRO MACROPHAGE
LYMPHOMA AND SYMMETRIC DIMETHYLARGININE
Inclusion criteria were: (1) cytologic AE histologic diagnosis of lymphoma by a pathologist; (2) measurement of serum SDMA level at any stage of disease; (3) routine abdominal ultrasound examination for cases prospectively studied, to identify evidence of renal lymphoma; (4) informed owner consent. Dogs with indolent lymphomas were not included. All treated cases initially received the 25-week Madison Wisconsin CHOP combination chemotherapy protocol using prednisone, vincristine, cyclophosphamide and doxorubicin. Complete remission (CR) was defined as resolution of lymphadenopathy AE previous imaging abnormalities attributed to lymphoma. Clinicians assessing remission status were not aware of SDMA levels. Cases include: (1) Dogs with a diagnosis of lymphoma and measurement of SDMA but no further assessment or treatment; (2) Dogs currently receiving CHOP in CR or partial remission (PR); (3) Dogs currently in CR after completing CHOP; (4) Dogs in relapse receiving rescue therapy; and (5) Dogs euthanized after relapse. Groups 2-5 include dogs with or without pretreatment measurement of SDMA. Creatinine was measured on a cobas Ò analyzer (Roche Diagnostics). Samples for SDMA measurement were submitted to IDEXX Laboratories, Inc., Markham, Ontario, Canada. Data were summarized with descriptive statistics. Differences between means were analyzed by t-tests and paired t-tests. Differences between medians were analyzed by Wilcoxon rank-sum and signed-rank tests. Correlations were examined by Spearman Rank method.
Fifty-two dogs are included to date with mean, median and age range of 8, 7 and 3-13 years, respectively. Fifty dogs had WHO Stage III-V multicentric nodal lymphoma, one dog had primary mediastinal lymphoma, and one dog had primary bilateral renal lymphoma with sternal lymphadenopathy. No dog had clinical or clinicopathologic signs of pre-existing chronic kidney disease when diagnosed with lymphoma. Results for serum SDMA and creatinine levels are shown in Table 1 .
Comparing all dogs with untreated lymphoma and all dogs with CR ranging from 1 week to > 2 years, differences between mean and median SDMA levels and mean and median SDMA:Creatinine were significant (P < 0.001), while differences between mean and median creatinine levels were not significant. Overall correlation between SDMA and creatinine was moderate (rho = 0.29, P = 0.04). In the one case where SDMA was measured twice prior to treatment, SDMA increased from 18 to 22 ug/dL over 37 days, while creatinine remained stable at 76-78 µmol/L (SDMA:Creatinine increased from 0.24 to 0.28).
Fourteen dogs had serial SDMA and creatinine measurements beginning before treatment and then after achieving CR. Eleven of these 14 dogs (79%) had elevated SDMA before treatment, of which 3 of these 11 dogs (which included the dog with primary renal lymphoma) also had elevated creatinine. All 11 dogs with increased SDMA at diagnosis had normal SDMA levels in CR, and differences in the means and medians from baseline were significant (P < 0.05). Ten of the 11 dogs also had normal creatinine levels when in CR. For the 2 dogs that did not have primary renal lymphoma but had increased pre-treatment creatinine levels, in one dog normalization of SDMA from 15 to 10 ug/dL may have been due to correction of pre-renal azotemia, as creatinine decreased from 149 to 109 umol/L, and SDMA:Creatinine decreased from 0.10 to 0.09. However, in the other dog, the decrease in SDMA from 90 ug/dL to 12 ug/dL was disproportionately large compared to the decrease in creatinine from 227 mmol/ L to 166 mmol/L, with SDMA:Creatinine decreasing from 0.47 to 0.07.
Five dogs had lymphoma in relapse. Results in these dogs were similar to those with untreated lymphoma, while results for dogs in PR were in between those of dogs with untreated lymphoma/ lymphoma in relapse, and dogs in CR.
No relationships between SDMA level and signalment were identified. Nineteen (38%) dogs had immunophenotyping. Differences in SDMA levels between dogs with B-cell and T-cell lymphomas were not significant.
Twenty-nine (56%) dogs had abdominal ultrasound examinations performed as part of staging. For the dog with primary bilateral renal lymphoma, at diagnosis, SDMA was 15 ug/dL, creatinine was 149 umol/L and SDMA:Creatinine was 0.10. In CR 4 months later, SDMA was 12 ug/dL, creatinine was 109 umol/L, and SDMA:Creatinine was 0.11. The dog relapsed 1 month later with mediastinal involvement, and SDMA was 21 ug/dL, creatinine was 105 umol/L, and SDMA:Creatinine was 0.20. Abdominal ultrasound examination was not repeated. Only one of the 27 dogs with multicentric nodal lymphoma that had abdominal ultrasound examinations had evidence of renal infiltration. Ultrasound examination of this dog was performed again 6 weeks and 6 months later, and on both examinations the lesion had resolved. At diagnosis SDMA was 22 ug/dL, creatinine was 92 umol/L, and SDMA:Creatinine was 0.24, and in CR SDMA was 8 ug/dL, creatinine was 105 umol/L, and SDMA:creatinine was 0.08. The dog with the highest SDMA level (90 ug/dL), had no evidence of renal lymphoma and had normal kidney architecture on ultrasound examination. No dog examined by ultrasound had ultrasonographic evidence of chronic kidney disease at diagnosis.
Serum lactate dehydrogenase (LDH) activity was analyzed retrospectively in 29 available samples as a marker of lymphoma metabolic activity. There was no correlation between LDH activity and SDMA levels. Markers of spontaneous tumor lysis were analyzed to investigate acute kidney injury secondary to tumor lysis as a potential cause of increased SDMA. All dogs had normokalemia at all stages. Two dogs with untreated lymphoma had hyperphosphatemia and 5 dogs had mild hypocalcemia, while no dogs in CR had hyperphosphatemia and 2 had mild hypocalcemia; these differences were not significant. Uric acid was prospectively measured in 8 dogs. Prior to treatment uric acid levels were: mean = 17 mmol/L, median = 16 mmol/L, range = 9 -28 mmol/L. When these dogs achieved CR, results were mean = 12 mmol/L, median = 12 mmol/L, range = 12 -14 mmol/L. These results were significantly different (P = 0.02). Uric acid levels were moderately correlated with SDMA levels (rho = 0.26, P = 0.04, N = 59). Although uric acid is eliminated by the kidney, uric acid levels were not significantly correlated with creatinine levels (rho = À0.08, P = 0.57) which may indicate that uric acidemia was caused more by increased release by lymphoma than by decreased renal excretion.
We conclude that some dogs with lymphoma and large tumor burden may have increased SDMA levels which may normalize if dogs achieve CR, and that SDMA should not be interpreted in these dogs as evidence of age-related chronic kidney disease. SDMA might have potential as a biomarker of treatment response in some dogs, although the data are insufficient to make firm conclusions in this regard. The data may be underpowered to detect relationships of SDMA to immunophenotype or other characteristics of the patients or malignancy. The pathophysiology of increased SDMA in dogs with lymphoma is unknown. If the assumption is correct that SDMA production is not increased by lymphoma, potential mechanisms include 1) reversible acute kidney injury, and 2) reversible decrease in SDMA excretion without compromise to other aspects of kidney function, with either of these mechanisms being secondary to renal infiltration below the threshold of routine sonographic detection, or kidney injury resulting from spontaneous tumor lysis.
SERUM INFLAMMATORY CYTOKINE VALUES IN CACHECTIC AND NON-CACHECTIC CATS WITH CANCER
AND NORMAL CATS. Erika L. Krick, Kathy Michel, Molly Church. University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, USA Cancer cachexia is a complex syndrome in humans associated with poor tolerance and response to treatment. Patients often have elevated serum inflammatory cytokines. Some cancer-bearing cats exhibit clinical signs of cancer cachexia. The study purpose was to compare body weight, body condition, complete blood count, serum chemistry and inflammatory cytokine values in cachectic and non-cachectic cancer-bearing cats and healthy cats.
Client-owned cancer-bearing and healthy cats prospectively underwent weight measurement, body condition and muscle mass scoring, complete blood count and chemistry panel, and serum amyloid A and alpha1-acid glycoprotein measurement. Cachexia was defined as muscle mass score below 2 and/or body condition score below 4. Seventy-two (17 cachectic, 27 non-cachectic, 30 healthy) cats have been enrolled. Mean body weight and body condition score were not significantly different among groups. Cachectic cats had significantly lower hematocrit and albumin compared to noncachectic (P < 0.0001, P < 0.0001) and healthy cats (P < 0.0001, P = 0.0003). Cancer-bearing cats had significantly higher white blood cell counts compared to healthy cats (P < 0.0001). Preliminary cytokine results showed that cachectic cancer-bearing cats had significantly higher serum amyloid A compared to non-cachectic and healthy cats (P = 0.0086, P = 0.05).
The similar body condition score and weight among all groups underscores the importance of specifically assessing muscle mass in cats with cancer. Differences in hematocrit, albumin, and serum amyloid A in cachectic versus non-cachectic cats suggest that therapies directed to the altered metabolic state of these cats combined with cytotoxic treatment is worth investigation. Soft Tissue Sarcomas (STS) represent up to 15% of all skin and subcutaneous tumours in dogs. Local tumour control with wide surgical margins or a combination of surgery and radiation therapy is the standard of care in the management of STS, however these approaches are not always possible due to anatomic location and/or expense of the treatment. Electrochemotherapy (ECT) is an emerging, locally ablative technique now available in the United States. ECT has been available in Europe for over a decade and is a standard therapy for cancer treatment in people and animals.
EFFICACY AND SAFETY OF ELECTROCHEMOTHERAPY
The purpose of this study was to evaluate the safety and efficacy of ECT with intravenous bleomycin in the treatment of STS in dogs.
Fifty-three client owned dogs with 55 STS were enrolled (two dogs each had two STS in different anatomical sites). Four dogs with STS located orally were excluded according to Bray (2016). Tumour location, size, histologic grade, electroporation parameters, recurrence rate, recurrence time, disease free interval (DFI) and treatment toxicity were evaluated. The owners elected to pursue ECT as an alternative treatment to surgery and/or radiotherapy. For all dogs, the diagnosis of STS was based on histopathology. Most dogs were staged with physical examination, fine needle aspiration of regional lymph node (if palpable) and three view thoracic radiographs. Complete blood cell count, minimal serum biochemistry profile and urinalysis were also obtained pre general anesthesia. For ECT treatment, dogs were premedicated with medetomidine (0.01 mg/kg, IM) and butorphanol (1 mg/kg, IM). Once sedated, patients were pre-oxygenated via face mask, and anesthesia was induced with intravenous alfaxalone (2 mg/kg). Dogs were intubated and anesthesia was maintained with oxygen, nitrous oxide and isofluorane. Atipamezole (0.05 mg/ kg IM) was administered to reverse medetomidine at the conclusion of the procedure. Bleomycin was diluted in saline solution and administered IV at a dosage of 15,000 UI (Pharmacopeia Europe)/m 2 (equivalent to 15 U-US Pharmacopeia /m 2 ). Treatment areas were prepared for surgery, skin was clipped and aseptically prepared with povidone-iodine wash (10% iodine) and surgical spirit. All dogs received anti-inflammatory and pain medicine in the peri-operatory period with meloxicam (0.2 mg/kg SC) and butorphanol. After ECT, all patients received antibiotic coverage (Amoxicillin + Clavulanic acid 12.5 mg/kg, BID, PO or Clindamycin 5.5 mg/kg BID PO) for at least one week. Patients were assessed every 3-10 days for the initial 4 weeks after ECT treatment, then monthly for three months. Thereafter, progress was monitored until at least 2 years either by examination of the patient or by telephone contact with the owner. Any progression in the treated tissue was recorded by digital camera images. ECT was performed using Cytopulse PA4000 in 9 cases or Cytopulse Oncovet in 46 cases (Cyto Pulse Sciences, Inc., now distributed by post-operative (adjuvant) ECT; this method was applied when the surgical resection of the tumour was initially performed attempting wide margins but where histological examination showed inadequate margins. Adjuvant ECT was applied after a period of 2-4 weeks from the surgical intervention (mean time 22.4 days). The reason for the delay was to perform ECT treatment as early as possible after adequate wound strength had developed following surgery and the final decision was left to the surgeon's judgement. In dogs receiving ECT alone, the tumour plus a 1-2 cm margin in all planes into grossly normal tissue were accessed by penetration of the electrode needles. The treatment was started in the margins and progressed concentrically into the tumour mass, thus avoiding transference of tumour cells from the centre to the margins. Moreover, this pattern of pulse application is reported to achieve better reduction of the blood flow to the tumour thus obtaining a better drug retention into the tumour stroma (Cemazar et al. 2016). Similarly, when ECT was used intra-operatively, a 1-2 cm margin in all directions was used. In dogs treated with ECT adjuvant to surgery, where there was no macroscopic disease, the treatment margin extended at least 1.5 cm from the healed surgical scar site in all planes. Local tumour response in dogs treated with ECT alone was evaluated according to the response evaluation criteria for solid tumors established by the veterinary cooperative oncology group consensus document (Nguyen et al. 2015) . A complete remission (CR) was defined as total reduction of the tumour. A partial remission (PR) was defined as ≥ 30% reduction in tumour diameter. Stable disease (SD) was defined as < 30% reduction in tumour diameter or < 20% increase in tumour diameter, and progressive disease (PD) was defined as ≥ 20% increase in tumour diameter. The presence of new lesions near to the primary tumour was considered as PD. A minimum duration of two to three weeks was required for a response to qualify as positive. In order to assess the local treatment toxicity a grading score (5-point scale) for tissue necrosis was established by the authors and previously described (Lowe et al, 2016): 0 = none, 1 = slight swelling, 2 = swelling/necrosis < 1 cm, 3 = severe swelling, 4 = deep necrosis and 5 = severe swelling and tissue loss. DFI was calculated from the date of treatment with ECT to the first recurrence or death of the animal unrelated to the tumour; or alternatively when we censored the DFI at the date we prepared this paper. The statistical analysis was performed using Chi-squared test and Fisher's exact test.
Of the 53 dogs included in the study, 22 were females (16 neutered) and 31 were males (14 neutered). The majority of dogs were pure breeds (38/53, 71.6%); Labrador Retrievers (8) and Staffordshire Bull Terrier (5) were over represented. Patient age ranged from 4 to 15 years (median 9.1). Tumour grade was assessed in 46 cases, most tumours were grade I (21/46, 45.6%) and II (23/46, 50.0%), only two were grade III (4.4%). The large majority of tumours affected the limbs (42/55, 76.4%), other locations were: trunk (8/55, 14.5%) and head (5/55, 9.1%). Tumour size ranged from 0.4 to 20 cm (median 4.5 cm). Median follow-up period was 482 days (range 8-2,483). The first ECT treatment was performed as follows: ECT alone in 5 cases, intraoperative ECT in 26 and postoperative (adjuvant) ECT in 24 cases. Five dogs underwent a second treatment due to tumour recurrence, in 3 of them a further recurrence occurred and a third ECT treatment was performed. The treatment response in the ECT alone group was as follows: two CR, one PR and two SD. At the end of the observation period, twenty-two dogs had died, of these, 7 had tumour recurrence, which was the reason for euthanasia in two cases. Of the other 29 dogs, 8 had tumour recurrence and in three cases the affected limb was amputated as rescue treatment. Patient outcome was not available in four cases. Overall, tumour recurrence rate (OTRR) was 27.2% (15/ 55). Recurrence rate was not associated with tumour grade, anatomical site, tumour size, pulse frequency and pulse voltage (P > 0.05). For all dogs, median DFI was not reached. For dogs with tumour recurrence, median DFI was 68 days (range 0-1,025). None of our patients developed systemic adverse effects related to the ECT treatment. Local toxicity was well tolerated in 65% of cases (36/55 had toxicity score ≤2 in a scale with 5 as maximum) and was not associated with tumour grade, tumour size and pulse frequency (P > 0.05). Local toxicity was associated with higher pulse voltage (1000 vs. 1200 V), which was statistically significant (P = 0.003).
The overall tumour recurrence rate (OTRR) of ECT alone or in combination with surgery (intra or post-operative) was 27.2%
Adjuvant ECT with local injection of bleomycin has been successfully applied in the treatment of canine sarcomas in a previous study (Spugnini et al. 2007 ). However, these results cannot be compared with ours because the tumour list included neoplastic entities that are no more considered as "true canine STS" (i. Chimeric Antigen Receptors (CARs) are synthetic receptors that combine an antigen-specific antibody moiety with T cell intracellular signaling domains. T cells that have been engineered to express a CAR can therefore recognize a specific antigen in an MHC independent manner and subsequently mediate potent cytotoxic responses against cells that express the target antigen. In this study, we aimed to determine whether canine T cells could be genetically modified using a second generation, CD20 targeting CAR and whether these re-directed T cells could proliferate in response to CD20 + target cells and become CD20-specific serial killers. We used a third-generation self-inactivating lentiviral vector to successfully deliver a second generation CD20-CD28-CD3-zeta CAR to canine T cells isolated from healthy dogs and dogs with B cell lymphoma. Cells were first activated using artificial Antigen Presenting Cells (aAPC) and then transduced with the lentiviral CAR. We demonstrate that canine T cells can be successfully re-directed and upon engagement with CD20, can undergo antigen-specific proliferation, cytokine production and serial killing. Having demonstrated proof-of-concept in vitro, we treated 4 dogs with B cell lymphoma with autologous, second generation, CD20 targeted CAR T cells. Although numbers of adoptively transferred CAR T cells were limiting, and B cell aplasia was not induced in any dog, we did observe evidence of in vivo CAR T cell activity. Taken together, this early data provides proof-of-concept that autologous CD20-targeting CAR T cell products can be generated from canine B cell lymphoma patients and should be further explored for the treatment of CD20 + malignancies. Lymphoma is one of the most common cancers in dogs. While remission is experienced in most dogs receiving chemotherapy, very few are cured, with median survival times typically in the 12-month range. Novel treatment approaches are needed. The IAP family member survivin, one of the most commonly overexpressed proteins in human cancer, plays a critical role in apoptosis resistance, a major cause of drug-resistant treatment failure. Therapies targeting survivin have shown promise preclinically; however, none have been evaluated in dogs to date. We demonstrated previously that survivin is abundantly expressed in canine lymphoma and osteosarcoma (OSA), and that high expression correlates with inferior clinical outcome. Furthermore, survivin inhibition with siRNA or the locked nucleic acid antisense oligonucleotide EZN-3042 reduced proliferation, increased apoptosis and enhanced chemosensitivity in canine lymphoma and OSA cells in vitro, and increased chemosensitivity in a canine OSA xenograft. The goal of this study was to investigate the safety and biologic effect of systemic EZN-3042 delivery in dogs with lymphoma. The primary endpoint was modulation of survivin expression in lymphoma tissues.
SURVIVIN INHIBITION WITH EZN
This was a prospective, phase-I dose-escalation trial in dogs with biopsy accessible multicentric lymphoma. Dogs received 3 biweekly doses of EZN-3042 as a 2-hour IV infusion. Starting dosage was 3.25 mg/kg. Escalation occurred at 1.25 mg/kg increments, according to a standard 3 + 3 cohort design. A CBC, serum biochemistry profile, coagulation profile and urinalysis were performed before the first and at each subsequent treatment. Peripheral blood mononuclear cells (PBMC) and tumor tissue were collected prior to the first treatment and 24 hours after the 3rd treatment. Adverse events (AEs) were graded according to the VCOG-CTCAE v1.1. Survivin expression was assessed in pre-and post-treatment tumor tissue and PBMCs utilizing qRT-PCR and immunohistochemistry (IHC). Tumor cell proliferation and apoptosis were assessed using Ki67 and activated caspase-3 IHC.
18 dogs were enrolled in 5 dose cohorts, ranging from 3.25 to 8.25 mg/kg twice weekly. 1 of 6 dogs treated at the highest dose cohort developed grade 3 thrombocytopenia. No other AEs were noted. Reduction in survivin mRNA was observed in PBMC and tumor tissue in 3 of 5 evaluable dogs treated at the highest dose cohort (8.25 mg/kg). Reduction in tumor survivin protein was observed in 3 of 6 cases at 8.25 mg/kg, but there was no correlation between protein and mRNA reduction. Reduction in Ki67 was observed in 2/5 cases, and increase in activated caspase was observed in 1/5 cases at 8.25 mg/kg. There was no correlation between survivin inhibition and changes in proliferation or apoptosis.
In conclusion, we have demonstrated reduction in survivin expression in lymphoma tissues and PBMC in the majority of dogs treated with EZN-3042 at a dose of 8.25 mg/kg twice weekly, a dose and schedule associated with acceptable toxicity. This biologically effective dose can be utilized in future studies evaluating EZN-3042/chemotherapy combinations in dogs with lymphoma and/or OSA. Cornell University, Ithaca, NY, USA Radioiodine is generally considered the treatment of choice for feline hyperthyroidism but can cause iatrogenic hypothyroidism in up to 75% of cats. However, these hypothyroid cats rarely develop overt clinical signs of the disease (hair-coat changes), and there are no published guidelines for how to diagnose or manage iatrogenic hypothyroidism in cats. Treating hyperthyroidism can also unmask subclinical chronic kidney disease (CKD), with up to 49% of cats developing azotemia by 3-6 months of treatment. Cats with iatrogenic hypothyroidism are more likely to develop CKD than treated cats that remain euthyroid; iatrogenic hypothyroidism can also reduce survival time, especially in cats with concurrent azotemia.Therefore, it is important to diagnose hypothyroidism in these cats, since thyroid hormone replacement might preserve kidney function and improve survival.
SMALL ANIMAL INTERNAL MEDICINE
In this study, we sought to determine which serum thyroid hormone or thyrotropin test best identifies iatrogenic hypothyroidism in cats that first develop azotemia after radioiodine treatment. Further, we sought to determine which test would best differentiate these azotemic, hypothyroid cats from azotemic sick euthyroid cats following radioiodine treatment, as well as from azotemic cats with CKD but no history of thyroid disease.
Five hundred and twenty-four hyperthyroid cats treated with radioiodine at the Animal Endocrine Clinic from June 2013 to June 2015 were evaluated for inclusion in this study. None of these cats had pre-existent azotemia (defined as serum creatinine >1.9 lg/dL), either when hyperthyroid or controlled with methimazole. Following radioiodine, 42 cats that developed post-treatment azotemia (creatinine >2.5 lg/dL) had serum concentrations of thyroxine (T4), free T4 by dialysis (fT4), and thyrotropin (TSH) measured at 3, 6, and 12 months. Iatrogenic hypothyroidism was confirmed (n = 28) or excluded (n = 14) in these 42 cats on the basis of thyroid scintigraphy. Fourteen cats with CKD and 166 clinically normal cats underwent similar serum thyroid testing and scintigraphy. Nineteen of the 28 cats with documented hypothyroidism had T4, fT4, and TSH reevaluated after 1-3 months of levothyroxine (L-T4) treatment to determine the influence of replacement therapy on these analytes. Serum concentrations of T4 and fT4 were lower and TSH higher in hypothyroid cats than in all three groups of euthyroid cats (P < 0.0001). Of the hypothyroid cats, T4 and fT4 concentrations were low in 15 (53.6%) and 7 (25%), respectively. Low serum T4 and fT4 concentrations were also measured in 7 (50%) and 2 (14.3%) of the cats with CKD. TSH concentrations were clearly high in all hypothyroid cats, whereas TSH remained within the reference interval in all three groups of euthyroid cats. After levothyroxine supplementation, serum T4 and fT4 increased and TSH concentrations decreased in all 19 cats treated, normalizing in 18. Serum creatinine also decreased significantly after L-T4 supplementation, with 4/19 (21.1%) cats becoming non-azotemic (creatinine ≤1.9 lg/dL).
Our results indicate that measurement of serum TSH concentration is a very sensitive and specific diagnostic test for iatrogenic hypothyroidism in cats that develop azotemic CKD after treatment. The finding of high serum TSH concentrations best identifies feline iatrogenic hypothyroidism and differentiates it from nonthyroidal illness syndrome in cats that develop azotemia following treatment. After L-T4 supplementation of cats with hypothyroidism, high serum TSH concentrations decreased to within the reference interval, indicating that serum TSH measurement can also aid in post-pill monitoring. L-T4 replacement in our hypothyroid cats also appeared to improve renal function, as indicated by the decrease in serum creatinine concentrations. Canine calprotectin (CP) and S100A12 have potential as markers of inflammation in dogs. Fecal CP and S100A12 concentrations were associated with clinical disease activity, and the latter also correlated with the severity of endoscopic lesions and the response to treatment in dogs with chronic enteropathies (CE). Serum C-reactive protein (CRP) concentration has been suggested as a monitoring tool for canine CE. The association between fecal CP and microscopic lesions or response to treatment has not been evaluated in dogs with CE. The aim of this study was to evaluate fecal CP concentrations in dogs with chronic inflammatory enteropathies (CIE) in relation to the severity of clinical signs, histologic lesions, fecal S100A12 and serum CRP concentrations, disease classification, and response to treatment.
EVALUATION OF FECAL CANINE CALPROTECTIN AS
Serum and fecal samples were collected from dogs with CIE. Fecal CP and S100A12 were measured using species-specific inhouse ELISA assays. Serum CRP was determined by a commercial ELISA test. Each dog was assigned a canine chronic enteropathy clinical activity index (CCECAI) score, and the severity of histologic lesions was assessed using the WSAVA grading system. Clinical response to treatment was either complete remission (CR), partial response (PR), or no response (NR). Cases of food-responsive diarrhea (FRD), antibiotic-responsive diarrhea (ARD), and steroidresponsive or -refractory disease (SRD) were distinguished. Statistical analysis was performed using non-parametric 2-group comparisons and a Spearman rho calculated for correlation analyses.
A total of 127 dogs diagnosed with CIE (median age: 7 years; 64 males/ 63 females) were included in the study. Median CCECAI score was 7 (moderate disease) and median histologic score was 2 (moderate lesions). Fecal CP concentrations ranged from 0.04-1,659.5 lg/g, and were correlated with CCECAI scores (P = 0.0111) and fecal S100A12 concentrations (P < 0.0001) but not with serum CRP concentrations (P = 0.1184) nor the overall severity of histologic lesions (P = 0.1705). However, fecal CP correlated with the increase in intraepithelial lymphocytes in the duodenum (P = 0.0059) and lymphoplasmacytic cells in the ileal lamina propria (P = 0.0282). Significantly higher fecal CP concentrations were detected in dogs with SRD than in those dogs with FRD or ARD (P = 0.0353). Within the SRD group of dogs, PR or NR was associated with higher fecal CP concentrations than CR, but the difference did not reach statistical significance (P = 0.0535).
We conclude that, similar to fecal S100A12 and in line with our previous findings, fecal CP may be a useful surrogate marker of disease severity and may have utility in predicting the response to treatment in dogs with CIE. Further research is needed to evaluate the utility of serial fecal CP measurements in dogs with CE and to compare the clinical utility of CP with that of S100A12. Platelet count alone is not predictive of bleeding severity or response to treatment for dogs with ITP. We evaluated dogs with severe thrombocytopenia to identify platelet abnormalities with potential diagnostic or prognostic relevance.
EXPANDED PANEL OF CYTOMETRIC MARKERS FOR
Flow cytometric assays detected platelet membrane-bound IgG and IgM (PsAIg), fibrinogen receptor (CD61) expression, and phosphatidylserine (PS) externalization. Microspheres conjugated with defined concentrations of canine immunoglobulin were used as assay controls. To assess sample stability, replicate analyses were performed on EDTA blood samples from healthy dogs (n = 7) through 72 hours of storage. Pre-treatment samples were also analyzed within 48 hours of collection from 21 dogs with severe thrombocytopenia (< 50,000 platelets/uL) in 3 categories: primary/autoimmune (PI, n = 7); infectious/lymphoproliferative/drugassociated secondary immune (SI, n = 7); non-immune (NI, n = 7) due to consumption or bone marrow suppression.
During storage, healthy dog platelets had stable CD61 expression but progressively increased PsAIg and PS externalization, with significant differences from baseline by Day 3 (Table 1) . While thrombocytopenic dogs had significantly higher median PsAIg than controls (IgG pos = 22% vs. 6.3%; IgM pos =23.6% vs. 7.3%; P < 0.01), the differences among disease groups were not Median values displayed; Bold = significant difference from Day 0 (P < 0.01, Dunn's multiple comparison test).
significant. Disease groups varied, however, in CD61 expression (significant decreases for PI and SI) and significant increases in PS externalization (SI) vs. controls ( Figure 1 ). Platelets from canine ITP cases typically lack the CD61 antigen, with an apparent increase in PS externalization for SI-triggered disease. These abnormalities may reflect membrane injury caused by immune targeting and activation or apoptosis induced by an underlying disease process. Together with PsAIg, these parameters may serve as biomarkers of active platelet destruction and metrics to guide treatment intensity. Immune-mediated hemolytic anemia (IMHA) has a high mortality rate due to thrombosis. Cell-free DNA from hypoxiainduced cell death and neutrophil extracellular trap release may contribute to IMHA hypercoagulability because it activates clot formation and impairs fibrinolysis. Reduced endogenous DNase activity reported in human autoimmune diseases may impair cellfree DNA clearance. We hypothesized that cell-free DNA would be increased in dogs with IMHA, in part due to reduced DNase activity.
CELL-FREE DNA, A POTENTIAL THROMBOSIS TRIGGER, IS INCREASED IN CANINE IMMUNE-MEDIATED HEMO
DNA extracted from plasma from primary IMHA dogs (n = 28) and healthy controls (n = 20) was quantified by DNA dye fluorescence. Serum DNase activity was measured using a DNA lysis radial diffusion assay. Thrombotic outcomes and death/euthanasia were recorded for 14 days.
Cell-free DNA was increased in dogs with IMHA compared with healthy controls ( Figure 1A ). DNA lysis area was not reduced in IMHA dogs. Four dogs died or were euthanized with thrombosis confirmed post-mortem. Surviving dogs had one confirmed and one suspected thrombotic event. Dogs with cell-free DNA in the upper quartile were at increased risk of death or euthanasia (odds ratio 15, 95% confidence interval 1.62-201; P = 0.04); there was no association between cell free DNA and thrombosis (odds ratio 2.4, 95% confidence interval 0.34-14.3, P = 0.57). Area under the receiver operator curve for cell-fee DNA prediction of death or euthanasia was 0.86 (95% confidence interval 0.69-1.0; P = 0.02, Figure 1B) .
Cell-free DNA is increased in IMHA dogs due to increased DNA release, rather than impaired DNA degradation. Cell-free DNA could have prognostic value in IMHA, but evaluation is needed in a larger cohort. the kallikrein-kinin system and regulation of vascular permeability. FXII deficiency is hypothesized to prevent pathologic thrombosis. Unlike other species, FXII deficiency is a common hereditary factor deficiency in cats. To date, two causative feline F12 mutations have been described: p.L441CfsX119, found in a feline research colony in the United States and p.G544A, identified in 2 Japanese DSH siblings. The aim of this study was to identify F12 mutations responsible for the high prevalence of feline FXII deficiency in the United States.
MUTATIONS CAUSING FELINE FACTOR XII DEFICIENCY
Study subjects included 17 unrelated pet cats (n = 14 Domestic Shorthair; n = 2 Domestic longhair; n = 1 Siamese) with Factor XII activity (FXII:C) ≤10% of normal. Genomic DNA was extracted from EDTA blood for amplification of all F12 exons, followed by direct amplicon sequencing.
Nineteen nucleotide differences were identified in the FXII deficient cats compared to the published feline reference sequence (GQ_981174). After exclusion of synonymous base changes and nonsynonymous changes present in cats with normal FXII:C, 3 mutations unique to FXII deficient cats remained (Table 1) . These mutations included the 2 previously described mutations and a novel mutation, p.G517X. The 17 FXII deficient cats were classified based on their combination of mutation-types: 1) p.L441CfsX119: Homozygous (HOM) and p.G544A: HOM (n = 9), 2) p.L441CfsX119: Heterozygous (HET) and p.G544A: HOM (n = 6), 3) p.G544A: HOM (n = 1), and 4) p.L441CfsX119: HET, p.G544A: HET, and p.G517X: HET (n = 1). F12 genotype was related to residual FXII:C. Cats classified as p.L441CfsX119 HOM (type 1) had ≤1 FXII:C%, whereas cats heterozygous or lacking this mutation (type 2 and 3) had moderate FXII deficiency (FXII:C = 3 to 10%).
The different mutation types were geographically widespread ( Table 1 ) and none of the cats had experienced abnormal bleeding. Future studies are warranted to identify potential beneficial effects of FXII deficiency in modulating the inflammation/coagulation axis that might explain the widespread propagation of inactivating F12 mutations in cats. College of Veterinary Medicine, Cornell University, USA, Ithaca, NY, USA Giardia are protozoan parasites capable of infecting a variety of mammals including both dogs and cats. Diarrhea is a common clinical manifestation of dogs presented to veterinary clinics and determination of Giardia infection status is a key consideration in the treatment of these patients. Fecal floatation using ZnSO 4 followed by microscopy is commonly used to identify Giardia cysts in-clinic. However, this method lacks sensitivity and specificity because cysts can be few in number, are shed intermittently, and are commonly not present in diarrheic feces. Direct immunofluorescence assay (DFA) using fluorescent antibodies directed against Giardia cysts has been shown to be more sensitive and specific than flotation methods and has been adapted as the gold standard for identifying fecal Giardia cysts. The DFA can only be performed in a specialized laboratory which limits its usefulness inclinic. More recently Giardia antigen detection assays that detect a soluble Giardia-specific cyst wall antigen have been developed and are available from several sources for use in-clinic. Comparison studies for the in-clinic assays are for the most part lacking. The purpose of this study was to compare the performance of in-clinic antigen assays using results of DFA as the gold standard. Four inclinic antigen test kits were evaluated: VetScan Ò Canine Giardia Rapid Test (Abaxis), Witness Giardia Test (Zoetis), Anigen Archived canine fecal specimens originally submitted by veterinarians to a commercial reference laboratory for general ova and parasite testing were used. These specimens were first examined by DFA for presence or absence of Giardia cysts using the Meriflour IFA detection reagent. This evaluation identified 101 cyst positive and 76 cyst negative samples. Fecal samples were tested on each of the 4 in-clinic assays following instructions supplied in the package insert for each kit.
PERFORMANCE OF FOUR IN-CLINIC TESTS FOR GIAR-
Compared to the DFA results, IDEXX SNAP was the most sensitive test, followed by the BioNote Rapid CPV/CCV/Giardia Antigen Test, then Zoetis Witness and Abaxis VetScan; specificity (highest to lowest) was IDEXX SNAP, Abaxis VetScan, BioNote Rapid CPV/CCV/Giardia Antigen Test and Zoetis Witness.
A limitation of this study is that the clinical status and environmental history of the dogs were not available for the samples evaluated. Notwithstanding this limitation, the results demonstrate that the SNAP Giardia test is the most accurate test among the 4 in-clinic tests evaluated. Tick-borne diseases in dogs are a growing issue worldwide and increasing emphasis is being placed on studying canine populations as sentinels for tick-borne diseases in people. The aim of this study North America (2 countries, n = 345,116); Caribbean (8 countries, n = 28,008); Latin America (13 countries; n = 17,587); Northern Europe (15 countries, n = 51,357); Southern Europe (13 countries, n = 57,446); Middle East-Africa (5 countries, n = 2,255 samples); and Asia-Pacific (9 countries, n = 83,720). Latin America had the highest overall positive results at 39.6%, followed by the Caribbean (28.7%), Middle East-Africa (25.9%), Northern Europe (25.1%), Asia-Pacific (12.9%), United States (11.6%), Southern Europe (10.6%), and OUS North America (3.3%). Seropositive rates by region for AP, EC, BB, along with a breakdown of the overall major co-infection (Co+) rates are summarized in Table 1 .
WORLDWIDE SNAP
This study represents the broadest worldwide canine tick-borne disease survey reported to date utilizing data from a single test platform. Co-infection data from this multiplex test may have use as an indicator of the predominant tick vectors to which dogs are being exposed in specific regions. Overall, the global seropositive rates documented in this study support the need for continued awareness of tick-borne diseases and monitoring the risks they pose to animal and public health. Seropositivity for BB (Table) varied among provinces over the study period (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) . Seroprevalence was highest in ON, QC, MB and within the maritime provinces of Nova Scotia (NS), New Brunswick (NB) and Newfoundland (NL), and lowest in the western Canadian provinces of Alberta (AB), Saskatchewan (SK) and British Columbia (BC). There were significant differences in prevalence among some of the provinces (P < 0.001). Assessment of Canadian complete year data (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) showed an annual increase in BB seroprevalence (P < 0.001). The magnitude of this shift was greatest within the provinces with the highest BB seroprevalence (ON, MB, QC and NS), and was most dramatic in NS.
PREVALENCE OF
Co-infections with BB were identified in 0.2% of tests (2007-2016), the most common being the combination of BB and AP (0.06%). Significant associations between BB seroprevalenceand co-infection with AP, E and HW ag were also noted (all P < 0.001). Further analyses of Canadian complete year data (2008-2015) revealed a positive association between increasing dog age and BB seropositivity; P < 0.001. Additionally, increased seroprevalence for both E (0.2 to 0.5%; P < 0.001) and AP (0.2 to 0.4%; P = 0.006) were observed between 2008-2015. A corresponding prevalence increase was not found for HW ag.
The increase in prevalence detected for most of these pathogens over time is consistent with anecdotal information on heightened seropositivity and disease in some regions of Canada; specifically a rise in Lyme disease in parts of ON, MB and NS. This improved understanding of the temporal and spatial changes in these vector-borne pathogens, together with the information on co-infections and additional study findings will serve as the base for future research efforts. The study highlights needs for targeted education and emphasis on preventive tick and mosquito health care across Canada, particularly within specific high-risk regions. The reported occurrence of acute kidney injury and overt acute renal failure in canine babesiosis is not well documented, mostly due to the use of different study populations and variable criteria to diagnose renal azotemia (RA). Furthermore, interpretation of urine specific gravity (USG) to assess renal concentrating ability is hampered by the presence of hemoglobinuria in babesiosis. The objectives of this study were to determine the occurrence of RA in dogs with babesiosis, using the gold standard to measure urinary concentration (i.e., urine osmolality), and to examine possible associations between the presence of RA and selected clinicopathological findings at presentation.
Data of 296 dogs, presented with babesiosis and included in 3 previously performed prospective studies, were reviewed retrospectively. Diagnosis of Babesia rossi infection was confirmed by PCR in all dogs. Cases were included in this study if a complete blood count, biochemistry profile, and urinalysis was performed at admission. All samples were collected before initiating fluid therapy. Urine osmolality was measured by freezing point depression in all azotemic dogs. Renal azotemia was defined as the presence of azotemia combined with urine osmolality < 1,110 mOsmol/kg (i.e., the equivalent of USG < 1.030). Differences between dogs with RA and dogs without RA were assessed by the Wilcoxon rank-sum test for continuous and ordinal categorical variables, while the Fisher's exact test was used for binary variables using a significance level of 5%.
A total of 152 dogs were included, of which 26 (17%) were azotemic at admission. The occurrence of RA was 14% (21/152), hence it was present in 21/26 (81%) of all azotemic dogs. When RA was defined as the presence of azotemia combined with USG < 1.030, only 6/26 (23%) of the azotemic dogs were considered to have RA.
Dogs with RA were significantly older than dogs without RA (P = 0.016). Dogs aged 7 years or older were 3.8 times more likely to present with RA compared to dogs younger than 7 years of age. Dogs with RA had a significantly higher body weight (P < 0.001) and lower body temperature (P = 0.036). Presence of collapse was significantly associated with the presence of RA (P = 0.007), while gender (P = 1.000), duration of illness (P = 0.137) and mean arterial pressure (P = 0.595) were not. Most hematological parameters were not different between both groups, except for band neutrophil count, which was significantly higher in dogs with RA (P = 0.013). Blood urea nitrogen (P < 0.001), total bilirubin (P = 0.039), serum hemoglobin (P = 0.003) and lactate concentrations (P = 0.026) were significantly higher in dogs with RA. Hyperphosphatemia (P < 0.001) and hypoglycemia (P = 0.002) were significantly more common in dogs presenting with RA, while the presence of systemic inflammatory response syndrome was not (P = 0.439). Visually, urine was significantly more turbid (P < 0.001) and darker (P = 0.009) in dogs with RA, while urinary protein (P = 0.781), bilirubin (P = 0.809) and hemoglobin concentrations (P = 0.052), assessed by dipstick analysis, were not different between both groups.
Our results clarify that RA is a common complication of babesiosis caused by B. rossi. This study also demonstrates that USG determination is not a reliable method to evaluate renal concentrating ability in azotemic dogs with babesiosis. As a consequence, 15/21 (71%) of the dogs with RA were misclassified as having prerenal azotemia when USG was used to classify azotemia. If urine osmolality cannot be measured, presence of several factors found to be associated with RA in this study could help to identify azotemic dogs that are more likely to have RA. Further work is needed to investigate the significance of these associations in relation to the pathogenesis of acute kidney injury caused by B. rossi. Ink4a is a molecular mediator of cellular senescence that has been shown to increase with age in the rat kidney. The purpose of this study was to explore p16
P16INK4A-MEDIATED
Ink4a as a possible senescence pathway for renal aging and disease in cats. P16 Ink4a was assessed in kidney tissue from 29 cats with chronic kidney disease (CKD; 10 cats IRIS Stage 2, 7 cats IRIS Stage 3, 13 cats IRIS Stage 4), 15 young non-CKD controls (10 years). Kidney sections were dual stained with p16
Ink4a and aquaporin-1 (AQP) immunohistochemistry to identify a proximal tubular epithelial cell population for analysis. Ten consecutive high power fields (60x) were evaluated from both cortical and corticomedullary junction regions by a blinded pathologist. Within each field tubules were designated either AQP+ or AQP-and the number of P16 Ink4a positive tubules counted. Semi quantification of tubular staining was also performed by assigning a score of the distribution of staining (none, focal, segmental, or diffuse). Sum of percentage of positive tubules and mean semiquantification scores were compared between groups using Kruskal-Wallis with Dunn's post hoc analysis.
CKD cats had significantly increased p16 Ink4a expression in comparison to young cats in all analysis categories: percentage p16
Ink4a cortex (P = 0.0003), percentage p16 Ink4a corticomedullary junction (P = 0.001), semiquantification cortex (P = 0.0002) and semiquantification corticomedullary junction (P = 0.0009). Geriatric cats had significantly increased p16
Ink4a expression in comparison to young cats in two analysis categories: percentage p16
Ink4a corticomedullary junction (P = 0.03) and semiquantification corticomedullary junction (P = 0.006). There was no statistically significant difference between CKD cats and geriatric cats for any of the analysis categories.
Results support p16 Ink4a as a mediator of senescence in geriatric cats and cats with CKD. Further work will be needed to determine if senescence in geriatric cats predisposes to development of CKD.
RAW FOOD DIETS ALTER THE MICROBIOME AND METABOLOME OF DOGS COMPARED TO COMMERCIAL. Jan S. Feeding raw food diets are gaining in popularity among dog owners. Feeding raw food has been associated with increased risk for transmission of bacterial enteropathogens. No detailed studies have been reported that evaluate the effect of raw food diets on the fecal microbiome and metabolome of healthy dogs. The aim of this study was to evaluate potential differences in microbial populations as well as functional metabolites in the intestine of healthy dogs fed either a raw food diet or commercial available wet or dry food diets.
Fecal samples were collected from healthy dogs fed a commercial diet (n = 20) and healthy dogs fed a raw food diet (n = 27).
The microbiota was analyzed by Illumina sequencing of the 16S rRNA gene and by qPCR for selected bacterial groups and calculation of the Dysbiosis Index. The metabolome was analyzed using an untargeted approach using a gas chromatography/mass spectrometry (GC/MS) platform and by targeted assays for fecal bile acid concentrations and sterols using GC/MS. Univariate statistics (Mann-Whitney test) were used to compare bacterial taxa and metabolic compounds between diet groups. P-values were adjusted for multiple comparisons using the Benjamini and Hochberg False Discovery Rate and significance was set at P < 0.05.
Significant differences in microbiota structure were observed between the diet groups (ANOSIM; P < 0.05), but microbiota richness was not significantly altered (P = 0.200). The Dysbiosis index was significantly increased in dogs fed a raw food diet (P < 0.001), and this increase was driven by an increase in E. coli (P < 0.001) and C. perfringens (P < 0.001). In contrast, Faecalibacterium was significantly lower in dogs fed a raw food diet. Several metabolites were altered between diet groups (e.g., 4-hydroxybutyric acid, tocopherol). Fecal cholesterol was significantly increased in the dogs fed a raw food diet, but no significant changes were observed for fecal bile acid concentrations.
In conclusion, dogs fed a raw food diet have an altered microbiome and metabolome when compared to dogs on a commercial diet.
CIPROFLOXACIN POPULATION PHARMACOKINETICS IN DOGS AFTER ORAL ADMINISTRATION.
Mark G. Papich. North Carolina State University, Raleigh, NC, USA Ciprofloxacin human generic tablets are frequently administered to dogs for treatment of bacterial infections because they are inexpensive and easily available. However, previous work by our laboratory indicated low and variable oral absorption in healthy research dogs. The aim of the study reported here was to examine a larger group of diverse patients from the North Carolina State University veterinary hospital. Ciprofloxacin intact generic humanlabel tablets (250 mg, 500 mg, or 750 mg) were administered to 34 client-owned clinical patients. The mean dog weight was 22.95 kg (range 4.6-57 kg). The mean age was 5.9 years (range 1-16 years). The mean dose was 23.5 mg/kg (AE4.75). We used a sparse sampling design so that blood samples were collected from each dog four times covering a time range of 0 to 24 hours. Population pharmacokinetic results were obtained using nonlinear mixed effects modeling and the Phoenix Ò NLME TM software (Certara, St. Louis, MO). The data was parameterized as a one-compartment model with first order input and elimination. The true values (theta) for volume of distribution and elimination rate were 10.7 L/kg (11.7%) and 0.16 /hour (7.62%), respectively. (All values shown as the estimate and CV %.) Secondary parameters were: T MAX 3.9 hours (10.1%), C MAX 1.9 lg/mL (11.66%), absorption half-life 1.78 hours (20.28%), and elimination half-life 4.35 hours (7.62%). Various covariates were examined to determine the source of variation. The size of the dog was an important covariate with larger dogs showing less oral absorption than smaller dogs. These data were used to estimate a breakpoint for susceptibility testing. Monte Carlo simulations were used to determine the probability of target attainment (PTA) for an AUC/ MIC ratio of ≥ 100, which is the accepted ratio for fluoroquinolones. Using this analysis, a breakpoint (susceptible) of ≤ 0.06 lg/mL should be considered when ciprofloxacin tablets are administered to dogs at a dose of 25 mg/kg once daily. This is much lower than the current human breakpoint of ≤ 1 lg/mL. Pancreatic islet transplantation could provide a cure for diabetes mellitus in dogs. Currently islet isolation is performed using harsh collagenases that cause non-specific injury to both islets and exocrine tissue, negatively affecting the outcome of cell transplantation. We evaluated a novel islet isolation protocol utilizing high concentrations of glucose to cause selective osmotic shock. Islets have a membrane glucose transporter (GLUT2) that allows adaptation to changes in glucose concentrations while exocrine tissue can be selectively destroyed by these osmolar shifts. Canine pancreata were obtained within 15 minutes after euthanasia from animals (n = 6) euthanized for reasons unrelated to this study. Each pancreas was divided into 4 segments that were randomized to receive 300 mOsm glucose for 20 min (group1); 600 mOsm for 20 minutes (group 2); 300 mOsm for 40 minutes (group 3); or 600 mOsm for 40 minutes (Group 4). Islet yield, purity and viability were compared between groups. Mean AESEM islet yield for Groups 1-4 was 533 AE 445, 616 AE 445, 1237 AE 445, and 1494 AE 445 islet equivalents per gram, respectively. Purity ranged from 37-45% and was not significantly different between groups. Islet cell viability was significantly affected by treatment group (P < 0.001) and was highest in groups 1 (90%) and 2 (89%), which experienced shorter durations of exposure to hyperosmolar solutions. Exocrine cell viability for these same groups was 36% and 45% showing selective cell destruction when compared to tissue. Selective osmotic shock provides a widely available means for researchers to isolate canine islets for use in islet transplantation or in studies of canine islet physiology. Current medical therapy options for canine hypercortisolism consist of mitotane and trilostane. While effective in controlling the clinical signs, both have disadvantages. Another approach in dogs with pituitary-dependent hyperadrenocorticism could be to block the glucocorticoid pathway by a melanocortin 2 receptor (MC2R) antagonist, i.e. an ACTH receptor antagonist. In cortisolsecreting adrenocortical tumors (ATs), suppression of steroidogenic factor 1 (SF-1) activity by SF-1 inverse agonists could be beneficial, as SF-1 is a critical factor associated with malignancy, but also steroidogenesis.
NOVEL MEDICAL APPROACH TO
This study was performed in vitro in cultured canine primary adrenocortical cells. Cell cultures were prepared from normal adrenals (NA, n = 8) and cortisol-secreting ATs (n = 6). Hypercortisolism was mimicked by incubation with synthetic ACTH. Cultures were treated with various concentrations of two different MC2R antagonist compounds (BIM-22776 (776) and BIM22A299 (299)), and three SF-1 inverse agonist (IsoQ A (SID7969543 (#IsoqA)), compound 31 (F1808-0154, (#31) and compound 32 (F1808-0165, (#32)). Effects on steroidogenesis were determined by cortisol measurements in the culture media, and mRNA relative expression of steroidogenic enzymes with RT-qPCR analysis. The effect of incubations on cell proliferation was evaluated by EdU assay.
Compound 229 significantly inhibited ACTH-stimulated cortisol production with a mean drop of cortisol production of 79% at 500 nM (p = 0.004) and 91% at 5000 nM (P < 0.0001). Compound 776 was less effective. Among SF-1 inverse agonists, #31 significantly (P < 0.0001 and P = 0.003) inhibited cortisol concentrations with a mean of 39% and 46% at 10 lM in ACTH stimulated and non-stimulated NA, respectively. In ATs, #31 was the most effective with a mean suppression of cortisol to 48% at 10 lM (P = 0.021). RT-qPCR data showed significant downregulation of steroidogenic enzymes in ACTH-stimulated cells treated with MC2R antagonist 229. Among SF-1 inverse agonists, #31 significantly reduced mRNA expression of CYP17 and CYP21. Effects of compounds on cell proliferation was only detectable in ATs and not in NAs. Incubations with #31 resulted in 45% suppression of proliferation.
We conclude that MC2R antagonistcompound 299 is a potent MC2R antagonist in vitro and could become a promising new treatment option for pituitary-dependent hypercortisolism. SF-1 inverse agonist #31 has a great potential in treatment of cortisol-secreting ATs, because it suppresses not only cortisol synthesis, but may also affects proliferation.
This in vitro study is a revolutionary approach to select the most potential treatment for canine hypercortisolism. It can lead to the development of new drugs and improvement of the current medical management. Colorado State University, Fort Collins, CO, USA Transdermal mirtazapine (Lipoderm gel) effectively increases appetite in normal cats. The purpose of this study was to assess the appetite stimulation properties of the transdermal mirtazapine in cats with chronic kidney disease (CKD).
ASSESSMENT OF TRANSDERMAL (LIPODERM) MIR
Nine client-owned cats with stable Stage II or III CKD and history of decreased appetite completed a double blind placebo-controlled crossover prospective study. Required diagnostics included serum biochemistry profile, complete blood count, urinalysis, urine culture, blood pressure, and total thyroxine measurement. Exclusion criteria included concurrent systemic illness, pyelonephritis, ureteral obstruction, or decompensation of CKD. Mirtazapine tablets were compounded into a 3.75 mg/0.1 ml dose transdermal Lipoderm gel by the CSU Veterinary Medical Center pharmacy along with an identical placebo. Predetermined randomization (AB or BA) was performed and as cats were enrolled they were assigned consecutively to a treatment regime. The randomly predetermined gel (A or B) was administered to the inner ear pinna every other day for three weeks and then crossed over after a 4 day washout. Owners documented appetite, rate of food ingestion, begging, activity and vocalization daily in the home environment. Physical exam, weight, body condition score, muscle mass score and serum biochemistry were performed at the end of each treatment phase. Change in weight, number of vomiting episodes over 21 days, and summed clinical scores for appetite, begging, vocalization and activity were compared between placebo and mirtazapine treatment phases using a Wilcoxon matched pairs test. Mirtazapine concentrations in compounded gel were measured using liquid chromatography/tandem mass spectrometry.
When CKD cats (six IRIS Stage 2 cats and three IRIS Stage 3 cats) received 3.75 mg transdermal mirtazapine every other day for three weeks a statistically significant change in weight (P = 0.008), increase in appetite (P = 0.05), and increase in rate of food consumption (P = 0.02) was seen. A statistical trend in increase in begging behaviors was seen (P = 0.06). No significant difference in activity or vocalization was seen. Median weight change after transdermal mirtazapine administration was 0.22 kg (range 0.04 to 0.44 kg) while median weight change during the placebo period was À0.04 (range À0.6 to 0.08). Improvement in body condition score was seen in 5/9 cats during mirtazapine administration and improvement in muscle mass score was seen in 3/9 cats. Gel concentrations varied by 77-114% (median 88%) of target dose.
Transdermal mirtazapine increased appetite and resulted in weight gain in CKD despite inconsistencies in compounding and may be helpful with the management of CKD-associated dysrexia. Survival times were calculated from the date of study inclusion to either death (all-cause) or right censoring. Cox regression was used to assess variables associated with survival including hematocrit, creatinine, CKD stage, serum phosphorus, UPC, PTH, 25 (OH)D, 1,25(OH) 2 D and FGF23.
RELATIONSHIP BETWEEN FIBROBLAST GROWTH FAC-
Significant hazard ratios (hazard ratio; 95% confidence interval; P value) were as follows: hyperphosphatemia (2.4; 1.2-8.8; 0.02), elevated UPC (3.2; 1.4-7.7; 0.01), and increased FGF-23 (2.7; 1.1-6.7; 0.03). CKD stage was also significantly associated with survival at all stages (P = 0.01).
In conclusion, in addition to other factors previously identified to be associated with survival time in dogs with CKD (eg, CKD stage, UPC, serum phosphorus), FGF23 was also correlated with survival. Pergolide is commonly used in treatment of pituitary pars intermedia dysfunction. However, there have been limited placebo-controlled trials evaluating efficacy of treatment. Furthermore, seasonal variation exists in both clinical signs and endocrine testing results, which may impact interpretation of treatment efficacy. The purpose of this study was to evaluate the impact of pergolide on endocrine test results and intramuscular adiposity from spring (May) to early fall (July).
EQUINE
Thirteen equids with PPID (based upon resting ACTH or ACTH response to TRH) were randomly assigned to treatment (n = 6; PERG) or placebo (n = 7; CON) groups. There were no equids with insulin dysregulation at study initiation. At enrollment, median body condition score was 4.5 (range 3 -6; PERG) and 4 (range, 3 -6; CON). Mean body weight was 513 AE 34 kg (PERG) and 458 AE 59 kg (CON). Horses were treated with Prascend Ò (1 mg/ horse) or placebo for twelve weeks starting in May. Twelve out of thirteen horses had a controlled diet for the duration of the study. Horses were weighed, and oral sugar tests, body condition scoring, and muscle biopsies performed prior to treatment (Week 0) and following 12 weeks of treatment (Week 12). Muscle biopsies were assessed for intramuscular fat using NMR. TRH stimulation tests were performed at Weeks 0, 4, 8, and 12. Dose of pergolide was increased by 1 mg in treated horses at Week 5 (n = 4) and/or Week 9 (n = 3) if ACTH concentration did not normalize or decrease by >75% from Week 0. Results were analyzed using two-way analysis of variance with repeated measures.
There was an effect of treatment on fasting insulin concentrations, with fasted insulin decreasing in PERG (P = 0.03) but not CON (P > 0.99) horses. There was an effect of time (P = 0.04) but not treatment (P = 0.17) on post-OST insulin. There was a significant time x treatment interaction for body weight, with PERG horses losing weight over time (P = 0.04). There was no effect of treatment or time on body condition score or intramuscular fat percent (P > 0.20). There was an effect of time on TRH stimulation results (P = 0.03) and a time x treatment interaction for resting ACTH (P = 0.001) and response to TRH (P = 0.005). The findings of this study suggest that treatment with pergolide in horses with PPID may decrease body weight and fasting insulin concentrations, without affecting intramuscular adiposity. Furthermore, implementing pergolide treatment in the spring may help limit the seasonal increase in ACTH. The purpose of this study was to evaluate the pharmacokinetics of oral trazodone and determine its effects on experimental and clinical horses for use as a long-term sedative. Six healthy adult horses were administered trazodone at 7.5 and 10 mg/kg in a crossover fashion. Plasma samples were collected for determination of trazodone and its active metabolite (m-CPP) via UPLC-MS/MS. Noncompartmental pharmacokinetic analyses were performed. Physical examinations, sedation and ataxia scores were determined following administration. Medical records of clinical cases treated with trazodone for behavioral disorders while on prescribed stall rest were reviewed and data collected. Trazodone was rapidly absorbed after oral administration with a maximum concentration of 2.5-4.1 lg/mL and an elimination half-life of approximately 7 hours. The metabolite was detected, although it only represented 2.5% of the total area under the curve. In experimental horses, concentration dependent sedation and ataxia were noted, beginning within 20 minutes of administration and lasting up to 12 hours. Trazodone was successful in modifying behavioral vices to some degree in 17 of 18 clinical cases at doses of 2.5-10 mg/kg once or twice daily. Tolerance developed in 2 of 18 clinical cases following 14 or 21 days of use. Adverse effects attributed to trazodone included over-sedation, muscle fasciculations and transient arrhythmias. Six horses received trazodone concurrently with reserpine with no apparent increase in adverse effects. In conclusion, oral trazodone can be used to cause sedation and facilitate stall rest in horses. Dose adjustments should be made based on individual response to the drug.7 Previously published myelographic studies do not report findings at the junction between the seventh cervical and first thoracic vertebrae (C7-T1). Current state-of-the-art radiographic equipment allows visualization of this area. Based on clinical experience, we hypothesized that a 50% reduction of the height of the dorsal myelographic column (DMC) as a supportive finding for spinal cord compression does not apply at C7-T1.
MYELOGRAPHIC FINDINGS AT THE CERVICOTHORACIC
Twelve healthy, neurologically normal Thoroughbred and Warmblood horses were included in the study. A myelographic study was performed under general anesthesia. Four independent observers assessed the myelographic studies for 50% reduction of the DMC at C6-C7 and C7-T1. A site was considered narrow if at least ¾ observers were in agreement. The dorsal myelographic ratios were calculated as the intervertebral DMC divided by the intravertebral DMC.
Narrowing of the DMC was observed at C6-7 and C7-T1 in three and six horses, respectively. The DMC ratio at C7-T1 was 52 AE 12%, while the C6-C7 DMC ratio was 67 AE 17% (mean AE sd). Based on these findings, 25% of horses would have diagnosed with myelographic evidence of spinal cord compression at C6-7 and 50% of horses would have been similarly diagnosed at C7-T1.
Narrowing of the height of the DMC is observed at C6-C7 and C7-T1 in horses without clinical evidence of spinal cord compression. This should be taken into consideration when assessing clinical cases. To avoid high numbers of false positive myelographic cases, applying a threshold of 60% narrowing of the height of the DMC (DMC ratio = 40%) at C7-T1 is advisable. The term occipitoatlantoaxial malformation (OAAM) is used to describe a developmental defect in which the first cervical vertebra (atlas) resembles the base of the skull (occiput) and the second cervical vertebra (axis) resembles the atlas. Affected individuals demonstrate an abnormal posture, with the neck extended, and varying degrees of ataxia. OAAM is presumed to be inherited as a monogenic autosomal recessive trait in Arabian horses. The homeobox (HOX) gene cluster is involved in the development of both the axial and appendicular skeleton. Hoxd3-null mice demonstrate a strikingly similar phenotype to Arabian foals with OAAM. We initially studied a radiographically confirmed OAAM affected horse, its sire and dam as well as seven unaffected Arabian horses. Whole-genome sequencing was performed at 12x coverage of the OAAM-affected horse. Visual inspection of the raw reads within the region of HOXD3 identified a 2.7 kb deletion located 4.4 kb downstream of HOXD4 and 8.2 kb upstream of HOXD3. The sire and dam were heterozygous for the deletion and it was not present in controls. Additional genotyping identified 2 other heterozygous Arabians and the deletion was not present in 159 other Arabians as well as 371 horses of other breeds. The 2.7 kb deletion was not detected in two additional Arabian foals diagnosed with OAAM. Closer examination of these cases revealed notable phenotypic variation, including facial malformations and a patent ductus arteriosus. Comparative genomic studies reveal that the region containing the deletion is highly conserved across species and that the entire genomic region between Hoxd4 and Hoxd3 is transcribed in mice. We conclude that a deletion between Hoxd4 and Hoxd3 is a rare occurrence in Arabians and, when present as a recessive trait, causes one but not all forms of OAAM. Genetic heterogeneity therefore exists across the HOXD locus in Arabian foals with OAAM. Salmonella enterica is one of the most commonly reported organisms associated with epidemic disease at veterinary hospitals, significantly impacting animal morbidity and mortality and adversely affecting the public's perception of these hospitals. Comprehensive screening and rapid detection of S. enterica in relevant samples is essential for effective infection control in high-risk populations. The objective of this project was to estimate the sensitivity and specificity of a commercially available rapid test strip for detection of Salmonella in comparison to optimized enriched aerobic cultures and a commercial PCR kit when used to test fecal samples via state-of-the-art, latent class ("no-gold-standard") analytical methods.
EVALUATION OF A RAPID TEST STRIP FOR DETECTION
One-gram fecal samples (n = 569) from equine patients were tested using 6 techniques: (1) tetrathionate broth (43C, 18 hrs) onto XLT-4 agar (43C, 18 hrs); (2) tetrathionate broth (43C, 18 hrs) onto hektoen enteric agar (36C, 18 hrs); (3) selenite broth (36C, 18 hrs) onto hektoen enteric agar (36C, 18 hrs); (4) selenite broth (36C, 18 hrs) onto XLT-4 agar (43C, 18 hrs), (5) rapid test strip, and (6) PCR. Data were stratified by expected prevalence (high versus low) for analysis based on previous surveillance data.
In general, the proportion of positive samples was greater when testing with the commercially available rapid test than with any other method evaluated, irrespective of prevalence group. Among low prevalence group -the proportion positive were similar for all culture methods and PCR testing; whereas, within the high prevalence group, the proportion positive was higher when using PCR testing as compared to the culture methods evaluated.
The findings of this project demonstrate the role test selection may have on the ability to detect Salmonella in equine fecal samples obtained from hospitalized patients. Having knowledge of a tests epidemiological sensitivity and specificity can greatly impact test interpretation in clinical practice. This study shows that commercially available rapid detection systems may be valuable tools when managing animal facilities, however users should be prepared to manage false positive test results. University of Pennsylvania, Philadelphia, PA, USA A low cost point-of-care "stall-side" diagnosis of strangles would greatly reduce the spread of this infectious disease by identifying S. equi subsp. equi in index or carrier horses. We previously demonstrated that the eqbE loop-mediated isothermal nucleic acid amplification (LAMP) assay was comparable to the seeI PCR in guttural pouch lavage samples. We implemented LAMP in a minimally instrumented microfluidic device that can use a cellular phone, offering point-of-care detection. We hypothesized that the point-of-care eqbE LAMP device was comparable to the benchtop eqbE LAMP assay and the triplex quantitative PCR 1 (qPCR). Stored guttural pouch samples from strangles convalescent horses were analyzed using a benchtop eqbE LAMP, eqbE LAMP on the microfluidic device, and the triplex qPCR 1 assay targeting S. equi specific genes eqbE and SEQ2190. Samples tested positive for S. equi were as follows: 31/64 on point-of-care eqbE LAMP with median results at 15 minutes (range 11 to 38 minutes); 27/68 on benchtop eqbE LAMP; and 12/67 on eqbE SEQ2190 triplex qPCR 1 . In comparison to triplex PCR 1 as a reference variable, benchtop eqbE LAMP showed excellent discrimination (ROC Area=0.813, 95% CI: 0.711-0.915). The newly developed point-ofcare LAMP also showed excellent discrimination power when compared to triplex PCR (ROC Area=0.811, 95% CI: 0.529-0.782). There was no significant difference between benchtop and point-of-care LAMP PCR (P = 0.974). Our point-of-care device and method could be used for fast, sensitive, accurate, and cost efficient diagnosis of strangles in the field. ALICAM is a veterinary-specific capsule endoscopy system that could be a breakthrough technology for diagnosing gastrointestinal (GI) pathologies in equine medicine.
VALIDATION OF STALL-SIDE STRANGLES DIAGNOSIS
The purposes of this study were to (1) Test the feasibility of ALICAM in horses, (2) Optimize protocols for shortest transit time and best visualization of the mucosa, (3) Measure transit time in healthy horses, and (4) Describe intestinal mucosa lesions in healthy and GI pathology cases.
Five healthy horses were used in a randomized crossover design to test 3 protocols. Three clinical cases with confirmed protein-losing enteropathies were also used.
Capsule recovery was tested using manure screening and radiography. Protocols were tested for three variables: fasting time, fluid volume administered, amount of exercise. Measured outcomes were: (1) Transit time, (2) Image quality score (image fields showing mucosa assessed by 2 observers), (3) Presence of GI mucosal lesions.
No side effects were noted. 3/20 capsules were not recovered. Radiography of manure was effective to recover the capsules. Battery life was 13.9 AE 3.5 hours. There was no significant difference in transit time between the 3 protocols. Transit time was 5.8 AE 2.9 days in healthy horses. The inter-observer agreement on image quality scores was excellent. Detailed images of the pylorus, duodenal papilla, villi, and ileocecal junction, but not the colon mucosa, were obtained. Lesions seen in healthy horses included fissures, ulcers, and submucosal hemorrhage. In addition, dilated lacteals were observed in clinical cases.
ALICAM allows measurement of transit time and detailed visualization of the pylorus and small intestinal mucosa in horses. In 2 horses, a ten-pole steerable catheter was placed in the coronary sinus. Under general anaesthesia, in dorsal recumbency, an 8.5 F bidirectional steerable basket mapping catheter with 8 splines and 64 low-noise electrodes (Intellamap Orion, Boston Scientific) was inserted through the jugular vein into the right atrium. The magnetic field generator for 3D localisation was placed over the left thorax. The right atrium and right ventricle were mapped using a stable coronary sinus electrogram and the surface ECG as timing reference, respectively. Subsequently, through a surgically inserted sheath in the right common carotid artery, the mapping catheter was advanced into the left ventricle under ultrasound guidance, and left ventricular mapping was performed. The left atrium was only mapped in one horse.
Three-dimensional geometry of the heart corresponded with ultrasound findings. Activation maps from right atrium, right ventricle and left ventricle could be generated and showed earliest atrial activation in the high right atrium. His bundle recordings were successfully recorded from the right atrium.
We concluded that high resolution 3D electroanatomical mapping is feasible in adult horses and provides a promising and powerful tool for electrophysiological research and for examination of complex arrhythmias.
HEART RATE MONITOR DERIVED HEART RATE VARI-ABILITY TO DIAGNOSE ATRIAL FIBRILLATION IN HORSES. Gunther van Loon, Barbara Broux, Dominique De Clercq, Sofie Ven, Lisse Vera, Glenn Van Steenkiste, Annelies Decloedt. Faculty of Veterinary Medicine, Ghent University, Belgium, Merelbeke, Oost-Vlaanderen, Belgium Atrial fibrillation (AF) is the most common clinically important arrhythmia in horses. Monitoring cardiac rhythm in successfully treated patients is important because recurrence may occur, but it might be challenging to the owner. Heart rate monitors are userfriendly, can be applied by owners and may offer basic heart rate variability (HRV) parameters such as root mean square of the successive differences (RMSSD) that might differentiate AF from sinus rhythm. The purpose of this study was to assess if RMSSD, automatically generated by a heart rate monitor, can distinguish between AF and sinus rhythm (SR), based upon a short recording. In 14 horses a 2-minute recording with a heart rate monitor (Polar V800) was made at rest, walk and trot, both in AF and after treatment when back in SR. RMSSD was obtained from the heart monitor's software after importing the recordings. Statistical analysis was performed using ANOVA and receiver operating curves. At all recording points, RMSSD was significantly higher in AF compared to SR (P < 0.001). Area under the curves were high (> 0.9) and cut-off values at rest, walk and trot were set at 134 ms (100% sensitivity, 93% specificity), 55.5 ms (94% and 73%) and 14 ms (100% and 87%), respectively. We concluded that RMSSD obtained from a 2-minute heart rate monitor recording is an easyto-use tool to monitor horses at risk for developing AF. Recordings at rest revealed best results. Loss of electrode contact and movement artifacts are possible confounders that increase RMSSD and may lead to false positive results. sample size, prior treatment, anaerobic growth, or formation of biofilm. The purpose of this study was to compare results of transtracheal aspirate samples identified by next generation DNA sequencing and traditional bacterial culture.
Transtracheal aspirate samples obtained from equine patients with suspected lower respiratory tract disease were submitted for next generation DNA sequencing (16S rRNA gene sequencing) and traditional bacterial culture. Samples were grouped according to whether prior antibiotic usage had been administered.
Fifty-five samples were collected from 55 horses. Thirty of the patients received antibiotic therapy prior. Next generation DNA sequencing identified 103 bacterial species whereas traditional culture identified 25 bacterial species.
Next generation DNA sequencing resulted in identification of more bacterial species than traditional bacterial culture and many of the bacteria identified by next generation DNA sequencing were not identified by bacterial culture. There were notable differences between the results of the next generation DNA sequencing when patients were grouped based on antibiotic usage. Increased knowledge of the microbial ecology provides veterinarians with the capacity to manage their patients more effectively. Next generation DNA sequencing is an important and valuable tool for practicing veterinarians because it allows them to survey the full bacterial landscape, not merely the culturable members of the microbial community. The normal distribution of data was examined; reference intervals were determined using bootstrap analysis and over-time differences were examined using Friedman test followed by posthoc analysis and adjusted P values were considered. Significant over time statistical changes were found between several values including WBC (P = 0.011) and MCH (P = 0.011) between days 2 and 90 and lymphocyte counts between days 2 and 180 (P = 0.033). Our results revealed over time differences for several hematological values, specifically at 2, 90, and 180 days of age. High WBC, lymphocyte, and monocyte counts after birth may be attributed to developing lymphoid systems while decreases in MCH may be a result of microcytosis secondary to decreased serum iron from an increased growth demand. The use of agebased reference ranges is critical for providing the most accurate diagnosis and optimum care in young foals.
CHANGES IN THE HEMATOLOGICAL AND BIOCHEMI-
Part B: The Changes in Biochemical Profile in Foals during the First Year of Life: Biochemical profiles of the equine neonate and foals significantly change throughout the first year of life. It is critical that clinicians use updated age-based reference intervals. Our objective was to provide an updated reference intervals for biochemical profile in foals at 2, 7, 14, 30, 90, 180 and 365 days of age and to examine statistical differences among those values among those ages. Left jugular venous blood was collected from 81 clinically healthy foals at 2, 7, 14, 30, 90, 180 and 365 days of age; submitted to and analyzed by a reference laboratory. Using routine laboratory techniques and following American College of Veterinary Clinical Pathologists guideline, 25 biochemical profiles were measured. The data normality was examined; using Bootstrapping analyses reference intervals determined and over time differences were examined using Friedman test following post-hoc analysis when appropriate and adjusted P values were considered.
Median, standard deviation and reference intervals for each of the measured variables were calculated. Several variables significantly differed including Calcium (P = 0.033) between days 2 and 180; Chloride (P = 0.033) between days 7 and 365 as well as Alkaline Phosphatase (P = 0.01964) and Magnesium (P = 0.014) between days 2 and 365. Observed physiological changes are related to growth and development of the animals which necessitate the use of age-based reference intervals. Our results revealed significant over time differences for several variables, more specifically at 30, 90, 180 and 365 days of age. The use of age-based reference ranges allows clinicians to provide most accurate diagnosis and optimum care in young foals. Pasture consumption is a risk factor for equine laminitis. However, the factors affecting insulin responses to grazing are poorly characterized. This study investigated whether pasture fertilization affected insulin and glucose responses to grazing in insulin-dysregulated (ID) and normal (IS) ponies (n = 16). Adjacent fertilized and unfertilized pasture was grazed for five consecutive days (for 4 h), in a randomized, cross-over design with an interim washout phase (10 days; lucerne hay). Blood samples were collected (0 to 8 h) for the first three days. Pasture intake was estimated using total fecal DM output and forage digestibility. Ponies were classified as IS or ID using oral glucose tests, but were otherwise healthy. The fertilized pasture had increased (P < 0.05) sward height and density but lower (P = 0.03) non-structural carbohydrate (NSC) content than unfertilized, which resulted in similar areas under the insulin curve (AUC insulin ) during grazing for both pastures. The AUC insulin and AUC glucose did not differ between sampling days and the mean values were positively correlated (P = 0.002). The NSC intake/cm height (wither) was positively correlated (P = 0.02) with AUC insulin , but not AUC glucose . Insulin Cmax and AUC insulin , but not AUC glucose , were greater (P < 0.05) in ID ponies for both pasture types, without a difference in pasture intake between groups. Thus, NSC intake, which is affected by pasture density and NSC content, is a more important predictor of pasture-associated insulin responses and laminitis risk than pasture fertilization status. Ponies with ID exhibit greater hyperinsulinism during grazing than IS ponies. One of the hallmarks of infection with herpesvirinae, including Equid Herpesvirus -1 (EHV-1), is the ability of the virus to establish latent infection during or shortly after lytic infection of the upper respiratory tract (URT) epithelium. As there is a connection between the URT and respiratory tract associated lymphoid tissue (RALT), EHV-1 latency is typically localized in respiratory associated lymphoid tissues (mandibular, retropharyngeal and bronchial lymphnodes, as well as the trigeminal ganglia (TG). Latent cell infection is characterized as a non-immunogenic infection with few viral genome copies per single cell, limited transcription of the immediate early-gene (IE) only, and, although not conclusively confirmed, the presence of additional (anti-sense) latency associated transcripts (LAT). The aim of this study was to determine whether latency is limited to RALT and/or TG in infection studies using EHV-1 wild-type (wt) or mutants strains.
INSULIN AND GLUCOSE RESPONSES
Three groups of yearling horses were infected intranasally with wt EHV-1, strain Ab4 (group I, n = 6), an EHV-1 polymerase mutant at position 752 (D>N) (group II, n = 9), or an EHV-1 glycoprotein D (gD) where gD of EHV-1 was replaced with gD of EHV-4 (group III, n = 8). All animals were euthanized 70 days post infection (p.i.). During post mortem examination TG, and RALT including, tonsillar pharyngeal roof tissue, mesenteric lymphnodes and spleen were collected. Viral genomic DNA and RNA were extracted, and RNA was converted to cDNA. Established primers and probes were used to detect viral DNA and cDNA transcripts of the immediate early (IE) gene and late (L) gene using quantitative PCR. Results are reported as either positive (pos) or negative (neg) for genomic DNA, IE-mRNA, and LmRNA. A tissue was considered latent-infected when IE-mRNA was detected while L-mRNA was not. Genomic DNA and IEmRNA were detected in animals of all three groups, while LmRNA was not. IE-mRNA copy numbers typically outnumbered genomic DNA copy numbers. IE-mRNA was detected in TG, as well as in RALT in all 3 groups, although with a different distribution between groups. In group III, for example, TG contained higher copy numbers of IE-mRNA than RALT, while in groups I & II copy numbers were higher in TG. Surprisingly, genomic DNA and IE-mRNA was also found regularly in mesenteric lymphnodes and spleen.
In conclusion, the number of IE-mRNA copies outnumbers viral genome copies during latency, which has been described for human herpes simplex 1 latency. We confirmed previously identified latency locations for EHV-1: RALT and TG. However, distribution preferences could be strain dependent. Moreover, EHV-1 latent infection of lymphoid tissue was not limited to RALT. and more prominent respiratory signs. Future studies should examine and further characterize the equine EHV-2/-5 dual infection model as a potential respiratory pathogen complex different from EHV-2 and -5 infection alone. eligible, a study had to include calves sampled between 1 and 10 days of age, and data allowing recording the number of true positives, false negatives, false positives and true negatives. Data extraction was performed by 2 different authors and any disagreement was resolved by a third author. For each threshold reported in 5 or more studies, pooled estimates of sensitivity and specificity were obtained using hierarchical models.
We identified 13 studies that all defined FPT as a calf with serum IgG.
In summary, when using refractometry to rule out FPT problem in herds, the 55 g/L cut-off could be used whereas for ruling in FPT problem in herds, the 52 g/L cut-off could be used. Respiratory disease in nursing beef calves often occurs during the first 30 days of life or around 90-150 days of age. Failure in the transfer of passive immunity or rapid decay of maternallyderived antibodies to respiratory viruses such as BVDV and IBR have been associated with this condition. The objective of this study was to determine the effect of vaccination with two doses of a killed virus (KV) multivalent vaccine containing BVDV 1, BVDV 2, and BHV-1 during late gestation on the level of total serum IgG and neutralizing antibodies to BVDV 1, BVDV, 2 and BHV-1 in newborn calves. 47 pregnant beef heifers previously vaccinated with a modified live virus (MLV) multivalent vaccine containing BVDV 1, BVDV 2, and BHV-1 before breeding were allocated into treatment groups. Group A (n = 20) received two doses of a KV vaccine 21 days apart between 6.5 to 8 months of gestation. Group C (n = 27) received 5 mL of saline in lieu of vaccination. Heifers were closely monitored for vaccine reaction, abortion, and normal parturition by personnel blinded to treatment allocation. Newborn calves were allowed to nurse colostrum naturally without assistance. Serum samples were collected from dams before vaccination and at calving and from newborn calves at 24 hours of age for neutralizing antibodies to BVDV 1, BVDV 2, and BHV-1. Additional serum was collected from calves at 24 hours to determine total IgG level. With respect to heifers, before vaccination the mean Log2 serum antibody titers to BVDV 1, BVDV 2, and BHV-1 were similar among groups A and C (P > 0.05). At calving, the mean Log2 serum antibody titers to BVDV 1, BVDV 2, and BHV-1 were higher in group A compared with group C (P > 0.05; Figure 1 ). With respect to newborn calves, the mean serum IgG levels at 24 hours were higher in calves born to heifers from group C compared with calves from heifers of group A (C = 31.7 g/L; A = 28.9 g/L; P < 0.05). The mean Log2 serum antibody titers to BVDV 1, BVDV 2, and BHV-1 at 24 hours was higher in calves born to heifers in group A compared with calves born to heifers in group C (Figure 2) . Vaccination of pregnant beef heifers during late gestation with two doses of a KV multivalent vaccine 21 days apart demonstrated to increase serum antibody titers to BVDV 1, BVDV 2, and BHV-1 at calving and at 24 hours in newborn calves. Higher serum antibody titers to BVDV 1, BVDV 2, and BHV-1 observed in calves born to vaccinated heifers might result in prolonged duration of maternally-derived immunity and better protection against respiratory disease during the pre-weaning period. Serum IgG at 24 hours in calves from this study could have been influenced by other factors different from the dam's vaccination protocol during gestation. Female crias (142/246, 57.7%) were significantly overrepresented in comparison to fillies (132/352, 37.5%). Congenital defects, failure of passive transfer, and clinical signs of prematurity were more often observed in neonatal crias, while colic, diarrhea, patent urachus, septic arthritis and omphalitis were significantly more common in CI foals. Foals also remained hospitalized for longer than crias (mean 6 versus 4 days; P < 0.001). Overall survival to discharge (excluding fatal congenital defects) was comparable between crias (174/224; 77.8%) and foals (287/347, 82.1%), while crias (26/48; 54.2%) were more likely than foals (21/60; 35%) to die naturally than undergo euthanasia. Lower respiratory disease and indications for oxygen or intravenous glucose support increased mortality in multivariate outcome models of both species. The latter analyses also associated ceftiofur treatment with better survival of crias and foals. A species-specific adaptation of pediatric diagnostic criteria of SIRS and sepsis was significantly associated with mortality in both species, including all animals with complete data sets.
MATERNALLY-DERIVED BVDV
A COMPARATIVE EVALUATION OF DIAGNOSTIC FIND-INGS AND MORTALITY RISKS IN HOSPITALIZED
Despite species-specific differences, the success of intensive care management is comparable between neonatal camelids and foals. America alone. The most common preventative measure used to reduce mortality in veal and dairy heifer raising operations is antimicrobials incorporated into the milk or milk replacer fed to the calves. Approximately 47.6% of dairy heifer producers fed an antibiotic in pre-weaned calves' milk. The majority of producers introduce antimicrobials prophylactically to calves immediately on arrival, or metaphylactically within the first week following arrival. As a result of the abundant use of antimicrobials in the veal industry, high levels of antimicrobial-resistant bacteria have been detected, as compared to the conventional cattle population. With antimicrobial resistance becoming of greater concern from both an animal and public health perspective, it is imperative to determine strategies to reduce antimicrobial use (and resistance) without comprising animal welfare.
Mycobacterium cell wall fraction (MCWF), Amplimune TM (NovaVive Inc, Canada), is the first immunostimulant licensed registered for bovine infectious disease therapy. Amplimune TM is indicated as an immunotherapeutic treatment in neonatal calves for the reduction of clinical signs and mortality associated with infection caused by K99 + enterotoxigenic Escherichia coli (ETEC), a major cause of diarrhea in neonatal calves. Amplimune TM has been shown to induce a non-specific immune response and participate in the development of both cell-mediated and humoral immunity. It could, therefore, be considered as either a stand-alone or adjunctive metaphylactic therapy to reduce the incidence of neonatal diarrhea and other neonatal diseases e.g., bovine respiratory disease complex (BRDC) and, consequently, the use of antibiotics in young calves.
The main objective of the study was to demonstrate the efficacy of MCWF in reducing the incidence of respiratory and gastrointestinal clinical conditions and reducing the use of antimicrobials administered as adjunct metaphylactic therapy to neonatal calves in a veal operation. A total of 699 calves, 1-10 days of age were randomly assigned to two experimental groups (N = 354 MCWF; N = 345 Control) and housed in four barns (Delimax, Quebec). Animals were group weighed on arrival and prior to slaughter. In addition to standard farm procedures and metaphylactic therapies (electrolytes and antibiotics) which were administered to all animals upon arrival, 1 mL of MCWF was administered subcutaneously to the treatment group (N = 345). This was repeated7 days later. Following MCWF administration, study calves were monitored daily for adverse events and all calves were treated if detected as being ill. Data were collected for the incidence of BRDC, diarrhea and other conditions for the duration of the study (154 days). Data for additional antibiotic usage, supplemental treatments (duration of use and costs) and weight of animals were also collected and analyzed.
The post-study analysis revealed that the incidence of clinical conditions that required treatment was significantly higher in the control group compared to the MCWF group (P < 0.0001; 123 vs 41). In addition, the volume of antimicrobials and supportive therapies administered in the control group was significantly higher than in the MCWF group (P < 0.0001; 1,090 mL vs.298.5 mL). Furthermore, the total number of calves requiring treatments was significantly higher in the control group than in the MCWF group (P < 0.01; 62 vs 42 calves). The total number of treatment days was 2.9 times higher (191 vs 65 days) in the control group than in the MCWF group. The average number of treatment days per calf was 1.6 days in the MCWF group versus 3.8 days in the control group (P < 0.01).
Based on a preliminary analysis of the data, MCWF (Amplimune TM ) can be used as an aid or an antimicrobial alternative to not only reduce morbidity and mortality but also reduce the number and volume of antimicrobials used in veal production. Further studies are underway to demonstrate MCWF efficacy as a standalone metaphylactic treatment in both dairy and beef calf operations. Salmonella enterica is a common enteric pathogen of domestic animals, especially in livestock such as horses and cattle, and has important implications for public health. Diagnostic testing is an important tool in the management of this agent, but there is no ideal or perfect test available. Poor sensitivity (detection of Salmonella in truly infected animals) is perhaps the biggest problem with available diagnostic tests. Aerobic culture is the most common traditional test that is used, and enrichment is considered essential to improve sensitivity. While sensitivity of aerobic culture is variable, it is recognized as generally having fairly poor sensitivity. Polymerase chain reaction (PCR) is the other common method used for detection of S. enterica, but enrichment is still required when testing feces or other types of samples that contain PCR inhibitors or have quantities of related bacteria in the samples, as is true of feces. Another type of molecular test that is commercially available for targeted detection of Salmonella are lateral flow immunoassays (LFIA) that use monoclonal antibodies for specific detection of Salmonella-specific surface antigens; these tests are designed for use in food safety applications, but have been explored for use in detection of S. enterica in feces. 1, 2 Recently, high-throughput genetic sequencing technologies have become highly affordable and widely available such that their use in research and clinical application is becoming increasingly common. Shotgun sequencing of metagenomic samples has the potential to open new avenues of research and provide improved understanding of the ecology of a various microbes such as S. enterica, especially when our understanding is undoubtedly colored by imperfect diagnostic tools.
COMPARING
The objective of this study was to compare aerobic culture, PCR, LFIA, and shotgun metagenomic sequencing as tools for detection of Salmonella enterica in fecal samples obtained from animals that had a high probability of infection and shedding.
This study was conducted as part of a trial evaluating the impact of metaphylactic antimicrobial treatment on the occurrence of antimicrobial resistance in fecal flora. Individual fecal samples were collected per rectum from 30 cattle upon arrival at a commercial feedlot, and again 11 days later. Each of the 60 samples was processed for testing in the 4 different tests. For aerobic culture, PCR, and LFIA testing, 4 grams of feces was enriched in tetrathionate broth at 42°C for 24 hrs before further processing. Samples of enrichment broth were plated to XLT4 agar for aerobic culture, and were tested in the LFIA. DNA was extracted from the broth for PCR testing using commercially available regents. For shotgun sequencing, metagenomic (whole microbial community) DNA was extracted from feces, and after library preparation was shotgun sequenced using the Illumina HiSeq 2000 platform. After sequencing, metagenomic reads were trimmed for increased quality and taxonomically classified with the Kraken software and the National Center for Biotechnology Information's (NCBI) RefSeq genome database.
Culture and PCR results showed 100% agreement, detecting S. enterica in only 0.05% (3/60) of samples. In contrast, there were positive LFIA tests in 22% (13/60) of samples, but none of these results agreed with culture or PCR results. Further testing of samples with the LFIA assay suggested that cattle eating high concentrate rations had a high prevalence of false-positive tests, which may explain these findings. In contrast with the results of culture and PCR which indicated a low prevalence of S. enterica shedding, initial analysis of shotgun metagenomic sequencing identified S. enterica in 60% (36/60) of samples. However, through further investigation it was recognized that the RefSeq genome database contains non-specific sequences found in individual isolates of one specific bacterial species that might be also found in isolates of other species. This is particularly true for mobile elements such as plasmids. As such, plasmid sequences are included within the reference genome files in the NCBI database, and as such plasmid sequences are considered to be specific to whichever bacterial species carried the plasmid when it was sequenced and submitted to NCBI. To investigate the impact of incorrectly classifying these plasmid sequences as being associated with a specific bacterial species, all of the plasmid sequences included with RefSeq genomes were identified and annotated to form one unique taxa representing all plasmids. Using this updated database, further analysis of the metagenomic sequencing data found that only 35% (21/60) of samples were classified as S. enterica, suggesting increased relative specificity. Not surprisingly, sequencing reads that were classified as belonging to plasmids in this subsequent analysis represented a small minority of all reads classified as bacterial. However, these plasmid reads were originally misclassified as representing sequences of bacteria belonging to 22 different phyla.
This study shows that the traditional techniques of aerobic culture and PCR provide similar results for Salmonella enterica identification in cattle feces but that shotgun metagenomic sequencing provides new opportunities for novel investigations of microbial ecology of this important pathogen. However, classification of bacterial species must be considered cautiously as the results are largely influenced by the reference database employed in the bioninformatic analyses.
